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 ABSTRACT 
         There is abundant evidence that animal studies in chronic renal 
failure show a major down regulation of hepatic cytochrome P450 
metabolism and hepatic functions are reduced; however, direct evidence in 
humans is lacking. 
         This study is carried out in the period from October 2003 to October 
2004 and the purpose of it is to outline the effect of chronic renal failure 
on human hepatic functions. Liver functions in Sudanese patients with 
chronic renal failure were studied. Study subjects were 45 patients (11 
females and 34 males) with chronic renal failure under regular 
heamodialysis (2 times per week) and 20 healthy persons (control). Blood 
samples were collected from the patients (pre-dialysis) and the controls in 
order to measure serum albumin, total protein, serum bilirubin levels as 
well as aspartate transaminase (AST), alanine transaminase (ALT) and 
alkaline phosphatase activities (ALP). 
          Chronic renal failure patients exhibited a decrease in serum albumin 
level (p<0.05) while total protein level and alkaline phosphatase activity 
were increased (p<0.05). Chronic renal failure did not alter AST and ALT 
activities. Serum bilirubin levels were unaffected.  
          From this study it is concluded that chronic renal failure has no 
clear effect upon the liver functions in humans and that it may be 
attributed to the positive effect of dialysis removal of toxins outside the 
body.   
 
 
 
 
 
  اﻟﺨﻼﺻﺔ
  ﻳﺆدى اﻟﻰ ﺧﻠﻞ ﻓﻰ وﻇﺎﺋﻒ اﻟﻜﺒﺪﻓﻰ اﻟﺤﻴﻮاﻧﺎت هﻨﺎك أدﻟﺔ واﺿﺤﺔ أﺛﺒﺘﺖ أن اﻟﻔﺸﻞ اﻟﻜﻠﻮى اﻟﻤﺰﻣﻦ
ﻻ ﺗﺘﻮﻓﺮ ﻣﺜﻞ هﺬﻩ اﻷدﻟﺔ ﻓﻰ ﺑﻴﻨﻤﺎ  اﻟﻜﺒﺪى   054 P emorcotyc  ﻣﺴﺘﻮى اﺳﺘﻘﻼب  ﻓﻰواﻧﺨﻔﺎض
 .اﻻﻧﺴﺎن
  وآﺎن اﻟﻬﺪف ﻣﻨﻬﺎ4002 اﻟﻰ اآﺘﻮﺑﺮ 3002أﺟﺮﻳﺖ هﺬﻩ اﻟﺪراﺳﺔ ﻓﻰ اﻟﻔﺘﺮة ﻣﻦ اآﺘﻮﺑﺮ            
 54واﺷﺘﻤﻠﺖ هﺬﻩ اﻟﺪراﺳﺔ ﻋﻠﻰ ﻤﺰﻣﻦ ﻋﻠﻰ وﻇﺎﺋﻒ اﻟﻜﺒﺪ ﻓﻰ اﻻﻧﺴﺎن، ﻣﻌﺮﻓﺔ ﺗﺄﺛﻴﺮ اﻟﻔﺸﻞ اﻟﻜﻠﻮي اﻟ
   ﻣﻦ ﻣﺮض اﻟﻔﺸﻞ اﻟﻜﻠﻮي اﻟﻤﺰﻣﻦ ﺗﺤﺖ اﻟﻐﺴﻴﻞ اﻟﺪﻣﻮى اﻟﻤﻨﺘﻈﻢ  ﻳﻌﺎﻧﻮن ﺳﻮداﻧﻴﺎﻣﺮﻳﻀﺎ
  . ﺷﺨﺼﺎ ﺻﺤﻴﺤﺎ ﻟﻠﻤﻘﺎرﻧﺔ02 ذآﻮر و 43 اﻧﺎث و 11ﻣﻦ ﺑﻴﻨﻬﻢ ( ﻣﺮﺗﻴﻦ ﻓﻰ اﻻﺳﺒﻮع ) 
  أﺧﺬت ﻋﻴﻨﺎت اﻟﺪم ﻣﻦ آﻞ اﻟﻤﺮﺿﻰ ﻗﺒﻞ اﻟﻐﺴﻴﻞ اﻟﺪﻣﻮى و آﺬﻟﻚ ﻋﻴﻨﺎت ﻣﻦ اﻷﺻﺤﺎء و ذﻟﻚ        
 niburiliB ﺒﻴﻠﻴﺮوﺑﻴﻦ   و اﻟ nietorp latot ال آﺎﻣﻞ اﻟﺒﺮوﺗﻴﻦnimublA ,ﻟﻘﻴﺎس ﻣﺴﺘﻮى ال 
 enilaklA. )PLA(و ) TPG,TOG( sesanimasnarT ﻧﺸﺎط اﻧﺰﻳﻤﺎت اﻟﻜﺒﺪ ال ﺎسوآﺬﻟﻚ ﻗﻴ
  esatahpsohp
ﺑﺎﻷﺻﺤﺎء  ﻓﻰ  اﻟﻤﺮﺿﻰ ﻋﻨﺪ ﻣﻘﺎرﻧﺘﻪ nimublA أوﺿﺤﺖ اﻟﺪراﺳﺔ أن  هﻨﺎك اﻧﺨﻔﺎض ﻓﻰ ﻣﺴﺘﻮى ال و        
    latoT. nietorp ﺒﺮوﺗﻴﻦ  اﻟ آﺎﻣﻞآﻤﺎ أن هﻨﺎﻟﻚ ارﺗﻔﺎع ﻓﻰ ﻣﺴﺘﻮى
 ﺑﻴﻨﻤﺎ ﻻ ﻳﻮﺟﺪ ﺗﺄﺛﻴﺮ ﻋﻠﻰ PLA( esatahpsohp enilaklA)ﻧﺸﺎط اﻧﺰﻳﻢ  اﻳﻀﺎ هﻨﺎك زﻳﺎدة ﻓﻰ
   TPG,TOG( sesanimasnarT. ) اﻧﺰﻳﻢ ﻧﺸﺎط و niburiliBﻣﺴﺘﻮى ال 
  ﻧﺨﻠﺺ ﻣﻦ هﺬﻩ اﻟﺪراﺳﺔ إﻟﻰ أن اﻟﻔﺸﻞ اﻟﻜﻠﻮى اﻟﻤﺰﻣﻦ ﺗﺄﺛﻴﺮﻩ ﻏﻴﺮ واﺿﺢ ﻋﻠﻰ وﻇﺎﺋﻒ اﻟﻜﺒﺪ ﻓﻰ
  .اﻟﻰ اﻷﺛﺮ اﻷﻳﺠﺎﺑﻰ ﻟﻠﻐﺴﻴﻞ ﻓﻰ ازاﻟﺔ اﻟﺴﻤﻮم ﻣﻦ اﻟﺠﺴﻢ  ذﻟﻚ  رﺑﻤﺎ ﻳﻌﺰى واﻻﻧﺴﺎن
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1-1 General introduction 
Renal failure has been recognized as a major health problem 
occurring in almost all population of the world. In Sudan, it has been 
disclosed from hospital records that the number of patients admitted to 
hospital suffering kidney diseases is increasing month after month and 
year after year.  
             Once renal failure occurs, requires immediate management such 
as dialysis and even then prognosis is often not good unless 
transplantation is done. 
             The chronic renal failure has a multiple complication that affects 
some organs in the body. One of them is the liver.  
The liver has a central metabolic role in the body. It is an 
important metabolic factory for plasma proteins, blood glucose and lipid. 
It is also a major site for detoxification and excretion of drugs, 
hemoglobin metabolites and ammonium ion. Its anatomic position as filter 
of splanchnic blood flow makes it a critical determinant of the 
pharmacodynamics of drugs and crucial for the detoxification of absorbed 
metabolic poisons from the colon. These roles become especially evident 
when the liver dose not do it's job.  
 Liver involvement with a variety of viral disease is a frequent 
finding in patients with end stage renal diseases on regular haemodialysis.  
Such patients are at increased risk for infection with hepatitis B virus 
(HBV).  
           Non renal clearance and the distribution volume of drugs are 
altered by chronic renal failure via changes in hepatic clearance, plasma 
proteins binding and tissue bindings.  
              Chronic renal failure can significantly affect the disposition of 
both low and high hepatic extraction drugs which are cleared 
predominantly by the liver. Hepatic clearance of low-extraction drugs is 
limited by intrinsic hepatic clearance and plasma protein binding. A 
reduction in intrinsic hepatic clearance will lead to reduced systemic 
clearance and produce an increase in steady-state plasma levels for both 
free and total drugs concentration of low-extraction drugs. Intrinsic 
hepatic clearance produced by down-regulation of hepatic cytochrome 
P450. 
This study was performed to determine the effect of chronic renal 
failure on liver functions and whether the liver is affected by the toxicants 
that are clear by the kidneys. That by assessment certain enzymes activity, 
bilirubin, total proteins and albumin levels in patients with chronic renal 
failure compared with persons without renal insufficiency.  
 It is reasoned that such an understanding was essential to learning the 
relation between renal disease and hepatic functions. 
 Objectives: 
           The aim of this study is to determine the effect of chronic renal 
failure on liver functions and whether the liver is affected by the toxicants 
that are produced from the kidneys.  
1- To measure blood urea and creatinine.  
 2- To assess the levels of electrolytes.  
 3-To measure the levels of serum bilirubin, total protein and albumin.                                 
4- To measure the activity of certain enzymes.  
5- To study the effects on sex and age on the level of these                               
parameters.  
      6- To study the impact of family   history   and   post   history on 
these   parameters. 
       1-2 The kidney:  
      1 -2-1 kidney Structure: 
         The kidneys are vital organs that perform a variety of important 
functions in the body. The human kidneys are paired; bean-shaped 
organs located in the retroperitoneal space. The right organ usually is 
more caudal, whereas the left organ tends to be slightly larger. Each 
adult human kidney weighs about 115 to 170 gram, measures 
approximately 11x 6 x 2.5 cm, and is surrounded by a tough, 
fibroblastic capsule. The kidney has a complex multicellular 
composition. The cut surface of a bisected kidney reveals a darker 
inner region, the medulla and a pale outer region approximately 1 cm 
in thickness, the cortex. The human kidney has a multi-papillary 
configuration in which the medulla is divided into 8 to 18 striated 
conical masses called pyramids. Each human kidney contains about 
0.8 to 1.2 × 106 nephrons, the functional units of the kidney. A 
nephron is a complex apparatus that consists of the glomerulus or 
renal corpuscle, the proximal tubule, the Henle's loop and the distal 
tubule. The connecting tubule, transitional segment, joins the nephron 
to the collecting duct system. Although not anatomically precise, the 
term nephron is commonly used to also include the entire collecting 
duct (Bennett,et al, 2000; Bishop, 1995). Figure (1) shows the 
anatomy of the kidney and the principal part of the nephron (Guyton, 
et al, 2001; Kumar, et al, 2003) 
 
 
        1-2-1-1 The glomerulus (the renal corpuscle): 
The glomerulus includes the glomerular tuft and the Bowman's 
capsule. The glomerular tuft contains three specialized cells, 
a basement membrane and a supporting   framework,   the mesangium. 
A fourth cell type, the parietal epithelial cells, lines Bowman's capsule.                        
Each glomerulus is supplied by an afferent arteriole carrying the blood 
in and an efferent arteriole carrying the blood out. 
    Bowman's space, also called urinary space, represents the 
area between the visceral epithelial cells (specialized cells) and the 
parietal epithelial   layer lining   Bowman's capsule.  A filtration 
barrier is formed between the blood and the urinary space by the 
peripheral glomerular   basement   membrane   (GBM) and   the 
overlying visceral epithelial cells.  In humans, the area of the 
filtration surface per glomerulus is approximately 0.136 sq mm. 
  The GBM is a hydrated gel containing cross-linked molecules 
that form a complex, type IV and V collagen, iaminin, heparin sulfate 
proteoglycans and nidogen or entactin as well as other components. 
The polyanionic character of the heparin sulfate proteoglycans is 
largely responsible for the net negative charge of the GBM.     
       1-2-1-2 The proximal convoluted tubule:  
    The proximal convoluted tubule is located in the cortical 
labyrinth and the straight portion of the cortex. The cells contain a                          
well-developed endocytic-lysosomal   apparatus that has an important 
role in the   absorption and degradation of macromolecules such as 
albumin from the glomerular filtrate. The localization of Na+, K+-
ATPase (the sodium pump) to the basolateral membranes explains the  
 
  
 
  
active transport of sodium characteristic of this tubule segment.          
1-2-1-3 The Henle's loop:  
     There is an abrupt transition from the terminal proximal tubule 
to the descending thin limb of Henle's loop at the junction between 
the outer and inner stripes of the out medulla. Short-looped nephrons 
have a short descending thin limb that continues into the thick 
ascending limb near the bend in the loop. Long looped nephrons have 
a long descending thin limb that enter the inner medulla, forms are 
lined with a low lying simple epithelium. The  sending  limb  located  
in  both  the  medulla  and  the  cortex (Bennett et al, 2000; Bishop, 
1995).  
       1-2-1- 4 The distal tubule:  
    The distal tubule includes two morphologically distinct 
segments: the thick ascending limb (TAL) of Henle's loop and the 
distal convoluted tubule (DCT). The TAL traverses the outer medulla 
upward in to the cortex near its glomerulus origin to end just beyond 
the macula densa. Thus the TAL can be divided into a medullary and 
a cortical segment.  
      The TAL is composed of cubical cells with extensive 
basolateral plasma membrane. The DCT represent the terminal part 
of the distal tubule and begins at a variable distance beyond the 
macula densa. The cells of the DCT resemble those of the TAL. 
    The connecting tubule or connecting segment joins the DCT 
with the collecting duct system. Representing a transitional segment 
in the human kidney, the connecting tubule composed of four specific 
cell types resulting from an intermixing of cells from adjacent DCT 
 and the initial collecting tubule (ICT). The most characteristic cell 
type is the connecting tubule cell, which is intermediate in 
appearance between the DCT cell and the principal cell of the 
collecting duct.  
      1-2-1-5 The collecting duct:     
The collecting duct is begins in the cortex and descends through 
the medulla to the tip of the papilla. It can be divided into cortical and 
medullary segments. There is remarkable cellular heterogeneity along 
the collecting duct.  
 The cortical collecting duct (CCD) can be subdivided into the 
initial collecting tubule (ICT) and medullary ray-portion. The CCD is 
composed of both principal cells and intercalated cells. The principal 
cells, which represent a pproximately   two   thirds   of the   total cells 
population, have a light-staining cytoplasm and relatively few 
organelles but prominent in folding of the basal plasma membrane. 
The intercalated or (dark) cells comprise approximately one third of 
the cells in the CCD (Bennett et al, 2000; Bishop 1995).  
       1-2-2 Kidney physiology:  
The complex multicellular composition of the kidney reflects the 
complicated nature of it functional properties. This organ is 
responsible for maintaining both the volume and ionic composition of 
the body fluids: excreting fixed metabolic waste products such as 
urea, creatinine and uric acid and eliminating exogenous drugs and 
toxins. The kidney is a major endocrine organ, because it produces 
rennin, erythropoietin, 1,2 dihydroxy cholecalciferol, prostaglandins 
and kinins. It also serves as a target organ for many hormones. The 
kidney also catabolizes small-molecular-weight proteins and is 
 responsible for host of metabolic functions (ammoniagensis and 
gluconeogensis).  
In a 70 kg person, a renal blood flow (RBF) amount is one fourth 
to one fifth of the resting cardiac output or 1.2 L/min. The renal 
cortex receives 85 to 90% of this flow compared with 10% for the 
outer medulla and 1 to 2% for the inner medulla including the papilla.  
RBF and glomerular filtration rate (GFR) remain relatively 
constant over a wide range of perfusion pressure, a process that is 
termed autoregulation. An intrinsic property of smooth muscle cells 
in the renal vasculature permits instantaneous alterations in the tone 
of the vessel wall to maintain RBF and GFR constant over a pressure 
range of 80 to 180 mmHg.  
   There are a host of hormonal and neural factors that can alter RBF. 
The three basic renal processes are glomerular filtration, tubular 
reabsorption and tubular secretion (Bennett et al, 2000; Bishop, 
1995).   
       1-2-2-1 Glomerular function:  
The glomeruli act as "filters" and the fluid which passes from the 
blood in the glomerular capillaries into Bowman's capsule is of the 
same composition of protein-free plasma. The effective filtration 
pressure which forces fluid through the filters is the result of:  
       1- The blood pressure in the glomerular capillaries.  
       2- The opposing osmotic pressure of plasma proteins. 
 The glomerular is the first part of the nephron to receive 
incoming blood and functions to filter this blood. Each substance 
such as urea, creatinine, amino acids, glucose and electrolytes except 
cells and large molecules continues into the proximal convoluted 
 tubule. In a 70 kg person, the kidney forms approximately 180 L of 
glomerular rate each day through a process termed ultrafiltration. 
This represents the initial step in urine formation. The driving force 
to move fluid from the glomerular capillaries across the glomerular 
capillary wall to the urinary space (Bowman's space) is derived from 
the hydraulic pressure that is generated by the pumping action of the 
heart. Each glomerulus has a filtration rate (single nephron 
glomerular filtration rate) (Sn GFR) of 60nL/min. The GFR is the 
volume of blood filtered per-minute. The rate of filtration is 
proportional to the net ultrafiltration pressure that is present across 
the glomerular capillary wall and is determinate by the balance of 
hydraulic and oncotic pressure that are operative between the 
glomerular capillary lumen and Bowman's space. Several factors 
facilitate filtration. One is the unusually high pressure in the 
glomerular capillaries, which is due to their position between two 
arterioles. Other factor is the GBM in both size-selective and charge -
selective barrier to the passage of macromolecules. The size-selective 
properties of the GBM allow molecules such as inulin, with radius of 
about 1.4 nm, to pass freely from the capillary lumen to the urinary 
space. As the radius macromolecules increases above 2.0nm, their 
passage is restricted across the GBM, and molecules with a radius 
greater that 4.2nm are completely restricted. Thus their fractional 
clearance approaches zero under normal circumstances. In addition to 
size, the charge of a molecule can greatly affect its ability to cross the 
glomerular capillary wall.  
The juxtaglomerular apparatus is believed to be responsible for 
tubuloglomerular feedback, in which the composition of tubular fluid 
 delivered to the macula densa changes the filtration rate of the 
associated glomerulus, presumably by altering rennin secretion, 
which ultimately regulates glomerular homodynamic (Chatterjea, et 
al, 1994).  
       1-2-2-2 Tubular function:  
      1-2-2-2-1 Mechanisms of tubular reabsorption and secretion: 
Small protein and some peptide hormones are reabsorbed in the 
proximal tubules by endocytosis other substances are secreted or 
reabsorbed in the tubules by passive or facilitated diffusion down 
chemical or electrical gradients or actively transported against such 
gradients. Movement is by way of ion channels, exchangers, co-
transported against and pumps. Renal active transport systems have a 
maximal rate, or transport maximum (Tm), at which they can 
transport a particular solute. Thus, the amount of a particular solute 
transported is proportionate to the amount present up to the Tm for 
the solute, but higher concentration, the transport mechanism is 
saturated and there is no appreciable increment in the amount 
transported.  
However, the Tm for some systems are high, and it is difficult to 
saturate them (Gonog, 1997). 
       1-2-3 Renal disease:  
Many diseases affect renal function. In some several different 
functions are affected, whereas in others there is selective impairment 
of glomerular function or of one or more tubular functions. The term 
glomerulonephritis encompasses group of renal diseases, which are 
characterized by pathological changes in the glomeruli with an 
immunological basis, such as immune complex deposition. 
 Glomerulonephritis may present in many ways as acute nephritic 
syndrome with heamaturia, hypertension and oedemma, and as acute 
or chronic renal failure.  
     Many disorders primarily affect renal tubular function but most 
are rare. Their metabolic and clinical consequences range from the 
trivial, such as renal glucosuria, to the severe cystinuria. Most types 
of renal disease cause destruction of complete nephrons. This is 
particularly true for the chronic renal failure.  
     Clinical investigations are mainly of value in detecting the 
presence of renal disease, by its effects on normal function, and in 
assessing its progress. They are of less value in detecting the cause of 
the disease. 
Glomerular function tests are essential steps in initial assessment 
of renal function. Tubular function tests are less convenient, since 
their performance usually requires conditions in which the tubules are 
stressed by artificial loading (Whitby et al, 1998; Marshall 1997).  
       1-2-3-1 Renal failure:  
Renal failure means failure of renal excretory function owing to 
a variable extent by failure of erythropoietin production, vitamin D 
hydroxylation, regulation of acid-base balance and blood pressure.  
     Renal failure results in reduced excretion of nitrogenous waste 
products of which urea is the most commonly measured. 
     A raised serum urea concentration (uremia) may conveniently be 
present in an individual patient.  
       1-2-3-1-1 Acute renal failure (ARF): 
      Means abrupt deterioration in parenchyma renal function which is 
usually, but not invariably, reversible over a period of days or weeks. 
 In clinical practice, such deterioration in renal function is sufficiently 
severe to result in uremia. Oliguria is usually, but not invariable a 
feature. Clinical features are determined by the underlying condition 
and by the rapidly developing uremia if the patient survives, renal 
function usually returns to normal or near normal (Kumar et al, 2003; 
Macsween et al, 1995).  
      The most commonly acute uraemia due to renal Parenchymal is 
acute renal tubular necrosis (Kumar et al, 2003). 
       1-2-3-1-2 Chronic renal failure: 
      Chronic renal failure (CRF) implies long standing and usually 
progressive, impairment in renal function. Chronic Renal failure is 
the major cause of death from renal disease. The healthy kidney has  
a large reserve of function and while the biochemical evidence of 
renal insufficiency will occur earlier it is only when around 75% of 
renal function has bean lost that the symptoms of CRF make 
themselves manifest.  
        1-2-3-1-2-1 Causes of chronic renal failure:  
 Chronic renal failure may be caused by any condition which destroys the normal structure and function of the kidney, the 
etiology of chronic renal failure are: congenital and inherited disease such as glomerular disease, that chronic renal failure due 
to atherosclerosis renal vascular disease is more common in the elderly than in the young (Kumar et al, 2003; Edwards et al, 
1995).  
       1-2-3-1-2-2 Clinical features of CRF:  
       The predominant symptom of chronic renal failure is tiredness, due mainly to accompanying anaemia. Urinary symptoms 
may include polyuria resulting from the osmotic diuresis. This in turn may cause polydipsia and thirst. Dyspnoea is common 
particularly in the older patient, due again to the anaemia and often also to heart failure. Hypertension may be a primary cause 
of chronic renal failure but much more often it is a sequel to the renal disease. Anoxia, nausea and vomiting are features of 
more advanced ureamia while neuromuscular feature include myopathy, peripheral neuropathy and encephalopathy with 
convulsions. Renal osteody strophy feature include muscle weakness, bone pain and hyperparathyroidism. There are 
endocrine abnormalities  
        (i) Anaemia:  
  Anaemia is present in the great majority of patients with                          
chronic renal failure. Several factors have been implicated: 
 erythropoietin deficiency, bone marrow toxins in renal failure and 
fibrosis secondary to hyperparathyroidism, haemostatic deficiency-
iron-vitamin B12 and folate, increased red cell destruction and 
abnormal red cell membrane causing increased osmotic fragility, 
increased blood loss occult gastrointestinal bleeding, blood sampling 
and blood loss during heamodialysis or because of platelet 
dysfunction.  
       (ii) Bone disease renal osteodystrophy:  
  The term renal osteodystrophy embrances the various form of 
bone disease which may develop alone or in combination in chronic 
renal failure hyperparathyroidism bone disease. Many patients with 
chronic renal failure are found histologically to have a mixed bone 
disease that is a combination of hyperparathyroidism (Kumar et al, 
2003; Edwards et al, 1995).  
       (iii) Skin disease:  
 Pruritus (itching) is common in severe renal failure and is 
usually attributed in the main to retention of nitrogenous waste 
products of protein catabolism. Other causes of itching include: 
hypercalcaemia, hyperphosphataemia, and hyperparathyroidism and 
iron deficiency.  
Chronic renal failure may also cause pseudoprophyria, results 
from decrease in hepatic uroporphyrinogen decarboxylase combined 
with decreased clearance of prophyrins in the urine by dialysis.  
      (iv) Endocrine function:  
      A number of hormonal abnormalities may be present. In female 
amenorrhoea is common due to absence of normal cyclical changes 
in female sex hormones, decreased serum testosterone levels, 
 complex abnormalities of growth hormone secretion and action, 
abnormal thyroid hormone levels, partly because of altered protein 
binding (Kumar et al, 2003; Edwards et al, 1995).  
      (v) Cardiovascular disorders:  
 Hypertension develops in approximately 80% of patient with 
chronic renal failure. It must be controlled, as it causes further 
vascular damage, thus increasing renal failure. Atherosclerosis is 
common due to abnormalities of lipid and carbohydrate metabolism 
and may be accelerated by hypertension.  
     (vi) Infection:  
 Both cellular and humeral immunity are impaired and thus there 
is increased susceptibility to infection. Urinary tract infections are 
common and must be treated, as they lead to further destruction of 
functioning renal tissue (Edwards et al, 1995).   
 
1-2-3-1-2-3 Investigations of CRF:  
There are some investigations by which diagnosis the chronic 
renal failure, urine, serum biochemistry, haematology, immunology, 
microbiology, radiological investigation and renal biopsy.  
      (A) Urine:  
1-Urinalysis: Haematuria may indicate glomerulonephritis but                  
other source my be considered, proteinuria, glycosuria with normal 
blood glucose. 
2-Urine microscopy: Eosinophiluria is strongly suggestive of allergic 
tubulointerstitial; granular casts are formed from abnormal in the 
tubular lumen and indicate active renal disease and red cell casts are 
highly suggestive of glomulonephritis.  
        3-Urine biochemistry: 
24 hour creatinine clearance is useful in assessing the severity of 
renal failure, urine osmolality is a measure of concentrating ability 
and urine electrophersis is necessary for the detection of light chains, 
which can be present without detectable serum proportion.  
       (B) Blood:  
        1-Serum biochemistry:  
 Urea, creatinine and electrolytes sodium and potassium, while 
the blood urea level will reflect the degree of renal failure it is also 
affected by dietary protein and rate of tissue break down and the 
serum ceratinine is more accurate guide to renal function. Other 
nitrogenous products whose blood levels are elevated include uric 
acid. Serum sodium is often normal but may be low due to decreased 
tubular capacity to conserve sodium. The same applies to potassium 
although in very advanced cases the blood level may become high 
hence the glomerular filtration rate falls to very low levels , or in 
association with oliguria or severe acidosis and is characterized by a 
lowering of the serum pH , pCo2 and bicarbonate. The serum 
phosphate rises due to the decrease in phosphate filtered and this is 
usually associated with a fall in serum calcium (Kumar et al, 2003; 
Macsween et al, 1995).  
       1-2-3-1-2- 4 Management:   
  The management of chronic renal failure falls into: 
1- The underlying cause of renal disease should be treated 
aggressively where possible and both family history and drug 
history are important.  
2- Blood pressure control :  
 Blood pressure should be reduced to 130/80 mm/h or lower. 
Adequate control may require combination of drugs together doses of 
diuretics to correct sodium and water retention.  
3- Hyperkalaemia:  
       It often responds to dietary restriction of the potentional 
should be stopped (Kumar et al, 2003; Edwards et al, 1995). 
4- Calcium and phosphate :  
      Hypocalcaemia and hyperphosphataemia should be treated 
aggressively, preferably with regular measurements of serum 
parathyroid hormone to assess how effectively parathyroidism being 
suppressed.  
5- Dietary restrictions :  
      In advanced renal disease, reduction of protein intake lessens the 
amount of nitrogenous waste products generated and this may delay 
the onset of symptomatic restricted in sodium and potassium.  
6- Fluid intake :  
      Fluid depletion and overload should be avoided. Dilutional 
hyponatraemia may occur if water intake exceeds the capacity to 
excrete the water load. Conversely, the large majority of patients with 
moderate chronic renal impairment do not need to restrict fluid intake 
(Kumar et al, 2003; Edwards ea t l, 1995). 
7- Drug therapy :  
     This should be minimized in patients with chronic impairment. 
Tetracyclines should be avoided in view of their antianabolic effect 
and tendency to worsen uraemia. Drugs excreted by the kidneys 
should be avoided.  
8- Anaemia :  
       The anaemia of erythropoietin deficiency can be treated with 
synthetic human erythropoietin, starting at a close of 25-50 u/kg three 
times a week; subcutaneous administration is more effective than 
intravenous. Blood pressure and hemoglobin connection and 
reticulocycte count are measured every two weeks. 
9- Replacement of renal function: 
      The excretory function of the kidney can be partially replaced by 
dialysis. The best results are obtained by an integrated approach to 
management, using the most peritoneal dialysis or transplantation for 
the patient depending on the clinical circumstances present. 
       (A) Haemodialysis: 
      In haemodialysis, blood from the patient is pumped through an 
array of semiperneable membranes which bring the blood into close 
contact with dialysate, flowing counter current to the blood. The 
plasma biochemistry changes towards that of the dialysate owing to 
diffusion of molecules down their concentration gradients (Kumar et 
al, 2003; Edwards et al, 1995). 
      The dialysis machine comprises a series of blood pumps, with 
pressure motions and blood leak detectors. Blood flow during dialysis 
is usually 200- 300 ml per minute and the dialysate flow usually 500 
ml per minute. The efficiency of dialysis in achieving biochemical 
change depends on blood and dialysate flow and the surface area of 
dialysis membrane (Kumar et al, 2003; Edwards et al, 1995). 
      The introduction of regular intermittent haemodialysis has 
prolonged the lives of many patients with chronic renal failure. 
Haemodialysis should be started when despite adequate medical 
 treatment, and preferable the patient has developed serious 
consequences of uraemia. 
      (B) Renal Transplantation: 
       This offers the possibility of restoring normal kidney function 
and thereby correcting the many metabolic abnormalities (kumar et 
al, 2003; Edwards et al, 1995). 
        1-3 The liver: 
       1- 2-1 liver Structure: 
The liver is the largest internal organ in the body and situated in 
the right hypochondrium.  Functionally, it is divided into right and 
left lobes by the middle hepatic vein.  The right lobe is larger and 
contains the caudate and quadrate lobes.The liver is further 
subdivided into a total of eight segments by divisions of the right, 
middle and left hepatic veins. Figure (2a) shows the segmental 
anatomy of the liver (Kumar et al, 2003).The blood supply to the 
liver constitutes 25% of the resting cardiac output and is via two main 
vessels: The hepatic artery supplies25% of the total blood flow.  Auto 
regulation of blood flow by the hepatic artery ensures a constant total 
liver blood flow. And the portal vein drains most of the 
gastrointestinal tract and the spleen. It supplies 75% of the blood 
flow.  The normal portal pressure is 5-8 mmHg; flow increases after 
meals. Both vessels enter the liver via the hilum (portal hepatic).The 
blood from these vessels is distributed to the segments and passes 
into the sinusoids via the portal tracts. Blood leaves the sinusoids, 
entering branches of the hepatic vein which join in to three main 
branches before entering the inferior vena cava. 
 The caudate lobe is an autonomous segment as it receives an 
independent blood supply from the portal vein and hepatic artery, and 
its hepatic vein drains directly into the inferior vena cava. Lymph, 
formed mainly in the perisinusoidal space, is collected in lymphatics 
which are present in the portal tracts.  These small lymphatics enter 
larger vessels which eventually drain into the hepatic ducts (Kumar 
etal, 2003). 
The functional unit of the liver is an acinus. This consists of 
parenchyma supplied by the smallest portal tracts containing portal 
vein radicals, hepatic arterioles and bile ductless .The hepatocytes 
near this triode (zone I) are well supplied with oxygenated blood and 
are more resistant to damage than the cells near the terminal hepatic 
(central) veins (zone 3). (Figure 2b) shows the diagram of an acinus  
(Kumar,et al, 2003).The sinusoids lack a basement membrane and are 
loosely surrounded by specialist fenestrated endothelial cells and 
Kupffer cells (phagocytic cells). Sinusoids are separated by plates of 
liver cells (hepatocytes). The sub-endothelial space that lies between  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
the sinusoids and hepatocytes is the space of Disse, which 
contains a matrix of basement constituents and stellate cells. 
Stellate cells store retinoids in their resting state and contain the 
intermediate filament, desmin. When activated they are contractile 
and probably regulate sinusoidal blood flow endothelin and nitric 
oxide play a major role in modulating stellate cell contractility.  
Stellate cells, after activation, produce collagen types I, III and IV 
(Kumar et al, 2003). 
       1-3-2 liver Functions: 
             The liver has important metabolic functions. 
       1-3-2-1 Protein metabolism: 
       (a)Synthesis: 
The liver is site of synthesis of all circulating proteins apart from 
α-globulins, which are produced in the reticulo-endothelial system. 
The liver receives amino acids from the intestine and muscles and, by 
controlling the rate of gluconeogesis and transamination regulates 
levels in plasma. Plasma contains 60-80 g/L of protein, mainly 
albumin, globulin and fibrinogen. 
        Reduced synthesis of albumin over prolonged period produces 
hypoalbuminaemia which is seen in chronic liver disease and 
malnutrition. Hypoalbuminaemia is also found in hyper-metabolic 
State and in diseases where there is an excessive loss (e.g. nephritic 
syndrome). 
       Transport or carrier proteins such as transferrin, caeruloplasmin, 
acute phase proteins and other proteins (e.g. α1- antitrypsin and α-
fetoprotein) are also produced in the liver. 
 The liver also syntheses all factors involved in coagulation (a 
part from factor VIII) that are, fibrinogen, pro-thrombin, factor V, 
VII, IX and XIII, protein C and S and anti-thrombin as well as the 
component of the complement system. 
       (b) Degradation (Nitrogen excretion): 
Amino acids are degraded by transamination and oxidative 
deamination to produce ammonia, which is then converted to urea 
and excreted by the kidneys. This is a major pathway for the 
elimination of nitrogenous waste.  Failure of this process occurs in 
severe liver disease (Kumar et al, 2003). 
       1-3-2-2 Carbohdyrate metabolism: 
Glucose homeostasis and maintenance of the blood sugar is a 
major function of the liver.  It stores approximately 80 g of glycogen.  
In the immediate fasting state, blood glucose is maintained either by 
glucose released from the break down of glycogen (glycogenolysis) 
or by newly synthesized glucose (gluconeogensis) from lactate, 
pyruvate, amino acids from muscle (mainly alanine and glutamine) 
and glycerol from lipolysis of fat stores.  In prolonged starvation, 
ketone bodies and fatty acids are used as alternative sources of fuel 
and the body tissues adapt to a lower glucose requirement (Kumar et 
al, 2003). 
      1-3-2-3 Lipid metabolisms: 
Fats are insoluble in water and are transported in the plasma as 
protein-lipid complex (lipoproteins). 
The liver has a major role in the metabolism of lipoproteins.  It 
syntheses very low-density lipoproteins (VLDLs) and high-density 
lipoproteins (HDLs). HDLs are substrate for lecithin cholesterol 
 acyltransferase (LCAT) which catalyses the conversion of free 
cholesterol to cholesterolester.  Hepatic lipase removes triglyceride 
from intermediate density lipoproteins (IDLs) to produce low-density 
lipoproteins (LDLs) which are degraded by the liver after uptake by 
specific cell-surface receptors. 
Triglycerides are mainly of dietary origin but are also formed in 
the liver from circulating free fatty acids (FFA) and glycerol and 
incorporated into VLDLs. Oxidation or denovo synthesis of FFA 
occurs in the liver, depending on the availability of dietary fat 
(Kumar et al, 2003). 
Cholesterol may be of dietary origin but most is synthesized 
from acetyl-CoA mainly in the liver, intestine, adrenal cortex and 
skin. It occurs either as free cholesterol, or is esterified with fatty 
acids, this reaction catalyzed by LCAT.  This enzyme is reduced in 
severe liver disease, increasing the ratio of free cholesterol to ester, 
which alters membrane structure. One result of this is red cell 
abnormalities seen in chronic liver disease. Phospholipids are 
synthesized in the liver (Kumar et al, 2003). 
       1-3-2-4 Formation of bile secretion: 
Bile consists of water, electrolytes, bile acids, cholesterol, 
phospholipids and conjugated bilirubin. Two processes are involved 
in bile secretion across the canalicular membrane of the hepatocyte- a 
bile salt-dependent and a bile salt-independent process, each 
contributing about 230 ml per day.  The remainder of the bile (about 
150 ml daily) is produced by the epithelial cells of the bile duct 
(Kumar et al, 2003). 
 Bile formation requires firstly the uptake of bile acids and other 
organic and inorganic ions across the basalateral (sinusoidal) 
membrane by multiple transport proteins, this process driven by Na+ - 
K+ ATPase in the basolateral membrane. Intercellular transport  
a cross the hepatocyte is partly through microtubules and partly by 
cytosol transport proteins. The canalicular membrane contains 
additional transporters, mainly ATPase-dependent, which carries 
molecules into the biliary canaliculi against a concentration gradient.  
The canalicular multispecific organic anion transporter (CMOAT) 
also known as multi drug-resistance protein 2 (MRP2) mediates 
transport of a broad range of compounds including bilirubin 
diglucuronide, glucuronidated and sulphated bile acids and other 
organic anions.  Na+ and water follow the passes of bile salts in to the 
biliary canaliculus by diffusion across the tight junction between 
hepatocytes (a bite salt-dependent process). In the bile salt-
independent process water flow is due to other osmotically active 
solutes such as glutathione and bicarbonate. 
The average total bile flow is approximately 600 ml per day.  An 
adequate bile flow is dependent on bile salts being returned to the 
liver by the enterohepatic circulation (Kumar et al, 2003). 
Bile acids are synthesized in hepatocytes from cholesterol.  The 
two primary bile acids, cholic acid and chenodeoxycholic acid are 
conjugated with glycine or taurine and this process increases their 
solubility.  Intestinal bacteria convert these acids into secondary bile 
acids, deoxycholic and lithocholic. 
 Bile acids act as detergents, their main function is lipid 
solubilization.  In aqueous solution they aggregate to form micelles.        
2-2-2-5 Hormone and drug inactivation: 
       The liver catabolizes hormones such as insulin, glycogen, 
estrogens, growth hormone, glucocorticoids and parathyroid 
hormone. It is also the prime target organ for many hormones (e.g.  
insulin).  It is major site of the metabolism of drugs and alcohol.  Fat 
soluble drugs are converted to water-soluble substances that facilitate 
their excretion in the bile or urine (Kumar et al, 2003). 
1-3-2-6 Immunological function: 
The reticuloendothelial system of the liver contains many 
immunological active cells.  The liver act as a sieve for the bacterial 
and other antigens carried to it via the portal tract from the 
gastrointestinal tract. These antigens are degraded by Kupffer cells, 
which are macrophages attached to the endothelium. Kupffer cells 
have specific membrane receptors for ligands and are activated by 
several factors such as infection (Kumar et al, 2003). 
The antigens are degraded with the production of antibody, as 
there is very little lymphoid tissue.  
The reticulo endothelial system is also thought to play a role in 
tissue repair, T and B lymphocyte interaction and cytotoxic activity in 
disease processes. Following stimulation by, for example, an 
endotoxin, the Kupffer cells release IL-6, IL-8 and TNF-α and play a 
key role in producing parenchyymal damage. These cytokines 
stimulate the sinusoidal cells, stellate cells and natural killer cells to 
release proinflammatory cytokines. The stimulated hepatocytes 
 themselves express adhesion molecules and release IL-8, which is a 
potent neutrophil chemo attractant (Kumar et al, 2003). 
       1-3-3 Biochemical test for liver disease: 
The mechanisms underlying hepatic diseases can be divided into 
three main groups; these often co-exist, but one usually predominates 
in any reflecting hepatocellular damage condition. Liver-cell damage 
is typified release of enzymes from damaged hepatocytes, which 
causes a rise in their plasma activities, cholestasis is typified by 
retention of conjugated bilirubin and alkaline phosphates (ALP) and a 
considerably reduced mass of functioning cell is typified by a 
reduction in prothrombin and albumin synthesis, which cause a 
prolonged prothrombin time and hypo albuminaemia (Zilva et al, 
1991).  
       1-3-3-1 Investigative tests can be divided into: 
         1-Blood tests: 
          (a) Liver function tests: 
i- Total protein. 
ii- Serum albumin. 
iii- Bilirubin. 
iv- Serum aspartate and alanine aminotransferase.     
v- Serum alkaline phosphatase,αglutamyltransferase. 
vi- Prothrombin time. 
           (b) Viral markers. 
   (c) Additional blood investigation haematological,                                                     
biochemical and immunological. 
         2- Urine tests: for bilirubin and urobilinogen 
         3- Imaging techniques:  to define gross anatomy. 
        4- Liver biopsy for histology. 
            Most routine liver function tests sent to the laboratory 
processed by an automated multichannel analyzer to produce serum 
levels of bilirubin, aminotransferases, alkaline phosphatase and total 
proteins (Kumar et al, 2003). 
       Liver function tests 
       (1) Serum albumin: 
Albumin is simple protein.  The molecular weight is 65000 
migrate faster in electrophoresis and precipitate last in salting out 
(Danish, 1997). 
It is synthesized in the liver about 10-12 g/day and has a half life 
of 16-24 days (kumar et al, 2003).  . 
About 60 percent of albumin in the extra cellular fluid is in the 
large intestinal compartment.  However, the concentration of albumin 
in the smaller plasma compartment is much higher because of the 
relative impermeability of the blood vessel wall.  This concentration 
gradient is important in maintaining plasma volume (Danish, 1997). 
Its main functions are first to maintain the intravascular oncotic 
pressure and second to transport water-insoluble substances such as 
bilirubin, hormones, fatty acid and drugs.  
Serum albumin is a marker of synthetic function and is a 
valuable guide to the severity of chronic liver disease. As falling 
serum albumin in the liver disease is a bad prognostic sign, in acute 
liver disease initial albumin levels may be normal.      
      (2) Bilirubin: 
              Bilirubin is produced mainly from the breakdown of mature red 
blood cells in the Kupffer cells of the liver in the reticuloendothelial 
 system; 15% of bilirubin comes from the catabolism of other haem-
containing proteins, such as myoglobin, cytochromes and catalyst. 
        Normally, 250-300 mg of bilirubin is produced daily.  The iron 
and globins are removed from the haem and this are reused.  
Biliverdin is formed form the haem and this is reduced to form 
bilirubin.  The bilirubin produced is unconjugated and water-
insoluble, and is transported to the liver attached to albumin.  
Bilirubin dissociates from albumin and is taken up by the hepatic cell 
membrane and transported to the endoplasmic reticulum by 
cytoplasmic proteins, where it is conjugated with glucuronic acid and 
excreted into the bile, the microsomal enzyme, uridine 
diphosphoglucurosyl transferase, catalyses the reaction. This 
conjugated bilirubin is water-soluble and is actively secreted into the 
bile canaliculi and excreted into the intestine with the bile.  It is not 
absorbed from the small intestine because of large molecular size.  In 
the terminal ileum, bacterial enzymes hydrolyse the molecule, 
releasing free bilirubin, which is then reduced to urobilinogen.  Some 
of this is excreted in the stools as stercobilinogen.  The remainder is 
absorbed by the terminal ileum, passes to the liver via the 
enterohepatic circulation and is re-excreted into the bile.  
Urobilinogen bound to albumin enters the circulation and is excreted 
in the urine via the kidneys (Danish, 1997). 
In the serum, bilirubin is normally almost all unconjugated.  
When hepatic excretion of conjugated bilirubin is impaired a small 
amount of conjugated bilirubin is found strongly bound to serum 
albumin, and leads to hyperbilirubinaemia for a short time after 
cholestasis. In liver disease, increase of serum bilirubin is usually 
 accompanied by other abnormalities in liver biochemistry. 
Determination of whether the bilirubin is conjugated or unconjugated 
is only necessary in congenital disorder of bilirubin metabolism or to 
exclude haemolysis (Danish, 1997). 
       3- Total proteins: 
Total protein estimation is of limited clinical value.  Acute 
changes in concentration, like those of proteins, reflect both the 
protein and the fluid content of the vascular compartment.  Acute 
changes are more likely to be due to loss from, or by the vascular 
compartment of protein-free fluid than of protein.  Only marked 
changes of the major constituents, albumin and immunoglobulins, are 
likely to alter total protein, levels significantly. 
                Low total protein levels may be due to: Dilution, if blood is 
taken near the site of an intravenous infusion, hypoalbuminaemia and 
profound immunoglobulin deficiency. 
       Raised total protein levels may be due to: Loss of protein (free 
fluid), which may lead to increase in one or more immunoglobulins. 
       Total protein levels may be misleading and may be normal in the 
face of quite marked changes in the constituent proteins, for example; 
fall in plasma albumin concentration may roughly be balanced by 
arise in immunoglobulin levels, most individual proteins, other than 
albumin, make a relatively small contribution to total protein, quite a 
large percentage change in the concentration of one of them may not 
cause a detectable change in total protein concentration (Zilva et al, 
1991). 
       The globulin fraction consists of many proteins that can be 
separated on electrophoresis. A raised globulin fraction, seen in liver 
 disease, is usually due to increased circulating immunoglobulins and 
is polyclonal. (Bennett et al, 2000). 
       4- Transaminases: 
       The aspartate (AST; GOT) and alanine (ALT; GPT) 
Transaminase are most commonly plasma enzymes measured as 
indicators of liver cell damage. Arise in plasma transminases 
activities is a sensitive indicator of damage to cytoplasmic or 
mitochondrial membranes even if there is no detectable impairment 
of function; the hepatic synthetic and secretary capacities are large; 
only severe and usually prolonged liver disease demonstrably impairs 
prothrombin and albumin synthesis (Zilva et al, 1991). 
AST is primarily a mitochondrial enzyme (80%); (20% in 
cytoplasm) and it is also present in heart, muscle, kidney and brain, 
high levels are seen in hepatic necrosis, myocardial infraction, muscle 
injury and congestive cardiac failure. 
ALT is a cytosol enzyme, more specific to liver so that arise 
only occurs with liver disease (Kumar et al, 2003).   
      5- Alkaline phosphatase (ALP): 
 Alkaline phosphatase is present in the canalicular and sinusoidal 
membranes of the liver, but is also present in many other tissues, such 
as bone, intestine and placenta. Its origin can be determined by 
electrophoretic separation of isoenzymes or bone-specific monoclonal 
antibodies. Alternatively, if there is also an abnormality of, for 
example, the  γ glutamy l transpeptidase, the ALP can be presumed to 
come from the liver. Serum ALP is raised in cholestasis from any 
cause, whether intrahepatic or extra hepatic disease.  The synthesis of 
ALP is increased in cholestatic jaundice; level may be four to six 
 times the normal limit. Raised levels also occur in conditions with 
infiltration of the liver and in cirrhosis, frequently in the absence of 
jaundice. (Kumar et al, 2003). 
Alteration in liver function  is not typically   present in patients 
with uraemic syndrome ,but varying  degrees of liver  dysfunction  
were observed  in animals  with  experimental uraemia  and  to lesser 
degree in patients with chronic renal failure . There was study 
investigated  the carbohydrate , lipid ,and proteins metabolism  in 
liver with  uraemia , particularly attention is given  to the role of 
cystoslic calcium (Ca++) regulation  and calcium signal transduction  
in hepatocytes in chronic renal failure . It is  proposed that  the  
parathyroid hormone (PTH) mediated  increase in the calcium ions  
of hepatocytes  in chronic  renal failure is the major signal  for the 
down regulation  of hepatic  receptors for hepatic  lipase , vasopressin 
,and angiotensin II. 
It is possible that the mRNA or other hormone receptors and 
various proteins of the liver cells are affected similarly by the 
elevated basal levels of (Ca++) in CRF (Omar et al, 1995). 
      Metabolic changes due to chronic renal failure were studied in 
isolated rats liver cells. To study gluconeogenesis, ureagenesis, 
oxygen consumption as well as cytosolic and mitochondrial adenine 
nucleotide content .CRF rat hepatocytes exhibited a 25% to 45% 
decrease in gluconeogenesis and ureagenesis while endogenous rates 
unaffected. CRF did not alter ketone body production from oleate or 
octanoate. Thus, this study of hepatocytes intermediary metabolism 
during CRF showed an alteration of only gluconeogenesis and 
ureagenesis pathway (Kaysen et al, 2004). 
  Pharmacokinetics studies conducted in patients with CRF 
demonstrated that the non-renal clearance of drugs is reduced. 
Although the mechanism of  by which  this occurs  is unclear , 
several  studies shown that CRF affects  metabolism  of drugs by 
inhibiting  key enzymatic systems in the  liver , intestine  and kidney . 
The down regulation of selected isoforms of the hepatic cytochrome 
P450 activity in CRF appears to be the accumulation of circulating 
factors which can modulate cytochrome P450 activity (Picette et al, 
2003). 
The cytochrome P450 oxidative enzyme system, located  
primarily in the liver  and  intestine , is responsible for  metabolism  
and  detoxification of numerous endogenous  and exogenous  
substances . 
 In experimental models of renal failure, both hepatic  function  
and  cytochrome P450 enzyme content are reduced, however direct 
evidence in humans is lacking .An association  between  renal disease 
and  reduced  hepatic metabolism has been observed in animal’s  
models ,in which significant correlation have been found between 
indices of renal function (blood urea nitrogen and serum creatinine 
levels )and hepatic  function (amino levulinic acid syntheses, amino 
pyrine ,N.demethylase and cytochrome P450) in animal models. 
       This finding suggests that  hepatic function (and drug 
metabolism) may be altered in renal  failure and  supports  the 
hypothesis that accumulation of ureamic toxins ,such as  organic ions  
and  phenol conjugates  may  inhibit hepatic  drugs metabolism by 
either reducing  cytochrome  P450 enzyme  content or  inhibiting 
uptake  of drugs  in hepatocytes (Dreisbach et al, 2003) . 
        There is abundant  evidence  that animal  studies  in  chronic  
renal  failure have  shown  a major  down regulation (40 – 85 %) of 
hepatic  cytochrome  P 450 metabolism  involving  specific isozyme. 
Phase II reactions such  as acetylation and glucourenidation are also 
involved with some  isoenzymes showing induction and  others 
inhibition .Hepatic enzymes exhibiting genetic polymorphisms as N-
acetyltransferase -2 (NAT-2)which is  responsible for the rapid  and 
slow acetylator phenotypes ,have been shown to be  inhibited by 
chronic renal failure and reversed by transplantation. There  is  some  
evidence pointing to the possibility  of inhibitory  factors  circulating  
in the serum  in chronic renal failure patients  which may be 
dialyzable .One mechanism of the reduced  non-renal  clearance 
appears to down-regulation  of protein  expression  of specific hepatic  
cytochrome P450 isozymes .This review  includes  all significant 
animal and clinical studies using the search terms “chronic renal 
failure “,”cytochrome P450 “ and “liver metabolism “ over the past 
10 years. Citations were derived from MEDLINE (1990 –2001) 
including relevant articles dating back to 1969 (Kliem et al, 1998). 
Chronic renal failure is associated with a decrease in liver 
cytochrome P450, the mechanism remains poorly understood. 
One study investigated the effects of the serum of rats with 
chronic renal failure on liver P450. In normal hepatocytes incubated 
for 24 hours with serum from rats with chronic renal failure, total 
P450 level, protein expression and mRNA levels of several P450 
isoforms were decreased by more than 35% compared to serum  from 
control animals . In conclusion uraemic serum contains mediator(s) 
 that down regulate the cytochrome P450 of normal hepatocytes 
secondary to reduced gene expression (Smogorzewski et al, 2003). 
               The chronic renal failure has effect on the disposition highly 
hepatically metabolized drugs that by changes in plasma proteins 
binding and on hepatic metabolism (Dowling et al, 2003). 
                Pantoprazole is a selective inhibitor of the gastric H+/K+ - 
ATPase with low potential to interact with the cytochrome P450 
       enzyme system. Since Pantoprazole  is  metabolized in the liver to 
metabolites  which are  mainly  cleared  by the  renal route , this is a 
study  that is to  investigate  its pharmacokinetics  in patients  with 
end stage renal failure undergoing regular haemodialysis. 
Pantoprazole was well tolerated. In particular these were no clinically 
relevant changes in blood count or liver enzymes (Cano et al, 1995). 
                Patients with end stage renal diseases on regular haemodialysis 
were screened for antibodies against hepatitis C virus (HCV) and 
hepatitis B surface antigen (HBSAg).All patients were examined for 
liver functions and serum proteins electrophoretic pattern. Some 
patients were negative  for both anti (HCV) and (HBSAg) Group I                                                
some patients were positive only for anti (HCV) Group II , and   other                                          
patients were positive for  anti (HCV) and (HBSAg) Group III , No                                                
significant correlation was noted between the elevation of liver 
enzymes and the groups studied, but a significant increase in total 
proteins and gamma globulin levels were absorbed in group II and III 
in comparison with group I. Serum albumin levels were significantly 
decreased (Yuan et al, 2000). 
        The concentration of albumin in serum is maintained by the rate of 
synthesis, catabolism and distribution between vascular and extra 
 vascular compartment .Albumin synthesis is suppressed when there is 
inflammation or inadequate protein intake. A decreased serum 
albumin  of  >  0.3 g/dl that persist for a period of  6 weeks  is 
associated with a decrease in albumin synthesis .This response is 
associated with evidence of activation of acute  phase response 
(inflammation ) , but not with change  in equilibrated normalized 
catabolic rate (enPCR).In well dialyzed patients , inflammation is the 
principle cause of a decrease in serum albumin while protein intake  
plays  an insignificant role .The decrease in serum albumin 
concentration was resulting from  reduced albumin synthesis and not 
a result of stable shift of albumin from the vascular to the 
 extra vascular pool , nor was it a consequence of dilution resulting 
from plasma volume expansion .As pointed out recently , the 
diagnosis of malnutrition as a sole cause of a low serum albumin in 
haemodialysis  patients would only rarely be appropriate (Guevinc  et 
al. 2002). 
2- MATERIALS AND METHODS 
2-1 Study design: 
    This study was conducted in Khartoum State during the period from 
October 2003 to October 2004. The study aimed to assess liver 
functions in specimens obtained from patients with chronic renal 
failure, using chemical analysis. 
2-2 Materials: 
2-2-1 Study population: 
    Fourty five patients suffering from chronic renal failure and 
undergoing haemodyalsis for duration of 60 months participated in this 
study. The patients included 11 females and 34 males of average ages 
between 15 years to 80 years. 
     All patients in this study who were asked to give blood specimens 
were briefed and consented for the purpose of the study.  The etiology 
of CRF was hypertension (N=17), diabetes mellitus (N=5), kidney 
disease N= (10) and unknown N= (13) where N = number of the 
patients. 
   Twenty healthy persons were also selected to participate in this 
study to serve as a control group.  All patients and control subjects were 
seen at the kidney haemodialysis unit, Khartoum Teaching Hospital, in 
which all clinical examination and assessment were done by physicians. 
Samples from patients and controls were taken after an informed 
consent. 
2-2-2 Sample collection and processing:  
      After wiping the skin with local antiseptic (70% ethanol), 5.0 ml of 
venous blood was taken with minimum stasis using sterile disposable 
syringes. Pre-analysis samples were then transferred to plain containers 
and allowed for 30-60 minutes for clot retraction, and then samples 
were centrifuged at 100g for 10 minutes. The sera were transferred by 
 pasture pipettes into glass containers and stored at 20 °C following 
methods of Vareley (Vareley, 1991). 
  2-3 Methods: 
The clinical assessment and chemical analysis of all parameters 
except bilirubin and electrolytes were done using a universal system 
called Vita Lab Selector, attached to a computer controlling the 
analyzer unit of the machine, collecting raw data and providing the 
user interface. Details of the system can be found as appendix. 
Bilirubin was measured by a manual procedure. 
2-3-1 Procedure:  
         Two ml of each of the prepared serum samples of patients and 
controls were entered in the Vita Lab Selector for estimation of 
albumin, total protein, alanine amino transferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), urea and 
creatnine. The samples were put in the tubes of Vita Lab Selector after 
being numbered. At the same time the calibrator tube was prepared by 
mixing reagent one with reagent two. An amount of two ml were then 
taken. Also two ml of distilled water was put in a tube as a blank. The 
45 samples of patients were done in 5 patches and the samples from 
control subjects were analyzed in 2 patches. The patch analyses took 
100 minutes and the Vita Lab Selector gave the results automatically.  
      The estimation of bilirubin was done manually by preparing two 
sets of tubes, one set was used for blank control samples and the 
second set for experimental samples. Then reagent one, reagent two 
and the samples were added. Contents of each tube were mixed well 
and the optical density was determined using a spectrophotometer.  
          Quantitative estimation of electrolytes was done by using a flame 
photometer. The blank was prepared by pippetting 5ml of distilled 
water into a tube. For other samples 5ml of distilled water was pipette 
 in clear tube and 0.05 ml of the standard solution was added to it. In 
addition 5 ml of distilled water were mixed with o.o5 ml of each of the 
serum samples. Then the serum would be read against the specific 
filter by the flame photometer.   
2-3-2 Estimation of Bilirubin: 
Principle:  Sulfanilic acid was expected to react with sodium nitrite to 
form diazotized sulfanilic acid. In the presence of dimethylsulfoxide, 
total bilirubin would react with diazotized sulfanilic acid to form 
azobilirubin. In the absence of dimethyl sulfoxide only the direct 
bilirubin would react to give azobilirubin. The Reagents of bilirubin 
were composed of two reagents, one was sulfanilic acid 28.9 mmol/L 
and Hydrochloric acid 165 mmol/L, (dimethy sulfoxide 7mmol/L in 
total bilirubin) and the other one was Sodium nitrite 43mmol/L. The 
calibrator used was BIEN- 4050. 
Procedure: 
 Sample blank  Sample 
Reagent (1) 1.5 ml  1.5ml 
Reagent (2) - 50 ml 
Sample  100ml 100 ml 
 
 After 5 minute incubation, contents were mixed again and the optical 
density (OD) at wavelength range of 555nm (530-580) was 
determined by the spectrophotometer. The spectrophotometer cuvette 
allowed 1 cm light path and the working temperature was 37ºC. The 
(OD) was proportionate with the colour intensity which was pink. 
 Calculation:  
With calibrator =         OD sample – OD sample blank           x n 
                           OD calibrator– OD calibrator blank  
 With factor        (OD sample) – (OD sample blank) XF 
n = Calibrator concentration. 
2-3-3 Estimation of Albumin (Alb): 
Principle: Serum albumin in the presence of bromcresol green at a 
slightly acid pH produced a colour change of the indicator from 
yellow-green to green-blue. The reagents of albumin detection were 
composed of succinate buffer pH 4.20 (75 mmol/L), bromocresol 
green (0.14 g/L) and brij 35 (7ml/L).The calibrator was ELICAL, a 
lyophilized calibration serum (36.39g/L). 
Procedure: The mode of this reaction was end point reaction and the 
unit was g/L. In the mono made normal volume (360Ml) and rerun 
volume (2Ml) were taken from the reagent as follows:                                                    
 OD sample 
 OD   calibrator  
n = Calibrator concentration. 
2-3-4 Estimation of total proteins: (TP) 
Principle: Serum proteins were expected to form a coloured complex 
in the presence of copper salt in alkaline solution (Biuret reactions). 
The total proteins reagents were composed of potassium iodide  
     (6 mmol/L), potassium sodium tartrate (21 mmol/L), copper sulfate  
(6 mmol/L) and sodium hydroxide (58 mmol/L). The calibrator was 
ELICAL (54.1 g/L).  
Procedure:    The mode of this reaction was end point reaction and 
the unit was g/L. In the mono made normal volume (300 ml) and rerun 
volume (301 ml) were taken from the reagent bottle and then added to 
normal volume (3 ml) and rerun volume (2 ml) of the sample. After 
that samples were incubated in the Vita Lab Selector for about 11.5 
x n 
 minutes. The optical density at wavelength 620 nm was read and 
results were calculated as follows:   
                       OD sample 
                             OD calibrator 
n = concentration of calibrator  
     2-3-5 Estimation of Alanine amino transferase (ALT) (GPT):  
Principle:  Kinetic determination of alanine aminotransferase (ALT) 
was based upon IFCC recommendation:  
     L-Alanine + α - ketoglutarate   ALT         pyruvate + L-Glutamatic  
     Pyruvate + NADH + H +         LDH        L-lactate+ NAD+ 
     LDH = Lactate dehydrogenase.  
      The ALT reagents were composed of two reagents one was Tris            
buffer pH 7.5(110 mmol/L), L-Alanine (600 mmol/L) and LDH (> 
1500 U/L) and the other one was α -ketoglutarate (16 mmol/L) NADH 
(0.24 mmol/L), the calibrator was (96.8 U/L 37ºC). Ten and volumes 
of reagent I were mixed with one volume of reagent 2. The reagents 
were stable 5 days at 20-25ºC or for 4 weeks at 2-8 ºC.  
Procedure: The mode of this reaction was kinetic and the unit was 
U/L. The working temperature was 37ºC. In this reaction, normal 
volume (250 ml) and rerun volume (262 ml) were taken from the 
reagent bottle and then added to normal volume (25 ml) and rerun 
volume (13 ml) of the sample.  After that the Vita Lab Selector read 
the optical density at wavelength 340 nm and the result calculated as  
follows: 
 Activity (U/L) = ∆ OD/ min x 1746 
2-3-6 Estimation of Aspartate aminotransferase 
(AST,GOT): 
x n 
 Principle: Kinetic determination of the aspartate aminotransferase     
(AST) based upon IFCC recommendation:  
L- aspartate + α -Ketoglutarate   AST        Oxaloacetate + L-Glutamate.  
Oxaloacetate + NADH+H+       MDH      L-Malate + NAD+  
MDH = Malate dehydrogenase. 
      The AST reagents were composed of two reagents; one was Tris 
buffer, pH 7.888 mmol/L, L-Aspartate 260 mmol/L, LDH≤ 1500 U/L 
and MDH ≥ 900 U/L. The second one was α- ketoglutarate 12 mmol/L 
and NADH 0.24 mmol/L. The calibrator was 106 U/L 37ºC. Ten 
volumes of reagent 1 were dissolved in 1 volume of reagent 2. The 
reagent was stable 5 days at 20-25º C or 4 weeks at 2-8 ºC. 
Procedure: The mode of this reaction was kinetic and the unit was 
U/L. The working temperature was 37ºC. In this reaction, normal 
volume (250 ml) and rerun volume (262 ml) were taken from the 
reagent bottle and then added to normal volume (25 ml) and rerun 
volume (13 ml) of the sample. After that the Vita Lab Selector read 
the optical density at wavelength 340 nm and calculated the result as  
follows: 
    Activity (U/L) = ∆ OD/ min x 1746. 
     2-3-7 Estimation of Alkaline phosphatase (ALP): 
Principle: Kinetic determination of the alkaline phosphatase was 
based upon DGKC and SCE recommendations: 
P -Nitrophenyl phosphate + H2O      ALP       P- Nitrophenol + 
Inorganic phosphate. 
     The reagents of ALP were composed of, diethanol amine buffer 
PHID.21.25 mol/L and magnesium chloride 0.625 mmol/L. four 
volumes of reagent 1 were mixed with one volume of reagent 2. The 
 reagent was stable 24 hours at 20-25 ºC (avoiding direct exposure to 
light), or 7 days at 2-8 ºC (avoiding direct exposure to light). 
 Procedure: The mode of this reaction was kinetic and the unit was 
U\L. The working temperature was 37 ºC. In this reaction, normal 
volume (250 ml) and rerun volume (252 ml) were taken from the 
reagent bottle and then added to normal volume (5 ml) and rerun 
volume (3 ml) of the sample.  After that the Vita Lab Selector read the 
optical density at wavelength 405 nm and the result was calculated as 
follows: 
 Activity (U/L) = ∆ OD/ min x 3424. 
2-3-8 Estimation of serum urea: 
Principle: Enzymatic determination was performed according to the 
following reactions: 
Urea + H2O   urease      2NH3 + CO2 
2NH4+   + 2 α - Ketoglutarate + 2 NADH    GDH       L Glutamate + 
2NAD+ 2H2O    (GDH = Glutamate dehyrogenase) 
     The urea reagents were composed of, Tris buffer, pH7.6 (100m 
mol/L), ADP (0.7 mmol/L), α- ketoglutarate (9 mmol/L), urease 
 ( ≥ 6500 U/L), GDH≥ 1 100 U/L and NADH (320 mmol/L). The 
calibrator was ELICAL (1,050 g/L). The working reagents were stable 
for 5 days at 20 - 25 °C or for one month at 2 - 8 °C. 
Procedure:   The mode of this reaction was two points reaction and 
the unit was mg/dl. The samples were incubated by the Vita Lab 
Selector 24,103 minutes and read the optical density at wavelength 
340 nm and calculated the results as the follows: 
                                            OD sample  
                                           OD calibrator    
n = concentration of calibrator. 
2-3-9 Estimation of serum creatinine: 
x n
 Principle: The rate of formation of a colour complex between 
creatinine and alkaline picrate was measured.  The effect of interfering 
substances was reduced using the kinetic procedure. 
   The reagents for detecting creatinine were composed of reagent one, 
picric acid (8.73 mmoI/L) and reagent two, sodium hydroxide (300 
mmol/L) and disodium phosphate (25m mol/L). The calibrator was 
ELICAL (34.7 mg/L). The working reagent was prepared by mixing 
one volume of the reagent I with one volume of reagent 2 and  stable 
for a month at 20 - 25 °C (contact with air was avoided). 
Procedure:   The mode of this reaction was two points reaction and 
the unit was mg/dl. The Vita Lab Selector incubation was for 24,103 
minutes and the optical density read at wavelength 505 nm and results 
calculated as the follows: 
                         OD sample  
                         OD calibrator                                                       
  n= calibrator concentration. 
    2-3-10 Estimation of electrolytes: 
Principle:  electrolytes were known to move either to cathode (-ve) 
charge or to anode (+ve) charge when supplied to electrical field and 
would carry either a negative or positive charge. 
The most common electrolytes were K+ and Na+ and they were 
measured by flame photometer, Na+ a major extra -cellular cation and 
K+ a major intracellular cation.  
Procedure: The selected K+ filter was (766 - 770 nm), the electrolyte 
button was switched on, gas was supplied, the flame was ignited and 
the distilled water was sucked with a pump that was used to adjust the 
blank as zero and wash the machine. The flame was adjusted until 
blue a concentration shape was formed, the standard (STD) was 
x n 
 sucked low at first and then high. After that distilled water was sucked 
for zero again. Then the specimens were sucked and read. The flame 
photometer calculated the results as: T/S x concentration of STD. 
The Na+ and K+ STD reagents were prepared by using, either Na+ 
chloride or K+ chloride.  k+ CL (mwt 74.5) was dissolved in one liter 
of distilled water. 
3-4 Analysis: 
Data collected was subjected to student's t test and analysis of 
variation (ANOVA) computer programs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
                                            3- RESULTS 
           This study aimed at studying the liver functions and their 
correlation with chronic renal failure of patients and the impact of 
different levels of the studied parameters on subjects under healthy 
conditions. 
       Fourty five patients suffering from chronic renal failure disease 
participated in this study; they included 34 males and 11 females 
between the ages of 15 to 80 years. Another twenty healthy subjects 
were also selected to participate in this study in which they served as a 
control group. Results obtained are presented in tables and figures. 
      Table (I) represented the means and standard deviation with 
minimum and maximum levels of urea, creatinine, K+ and Na+, in 
chronic renal failure patients. 
     Table (II) shows the means, standard deviation with minimum and 
maximum levels of total protein, albumin, transaminases, alkaline 
phosphatase and bilirubin. 
     Table (III) and figures (3-9) illustrate the levels of serum total protein, 
albumin, transaminases, alkaline phosphatase and bilirubin in healthy 
subjects as well as in chronic renal diseased patients, we can see from 
the table and figures that transaminase and bilirubin levels in both 
control and diseased subjects are nearly the same in which no 
significant difference in the level between the two study groups was 
seen. Transaminases being GOT 21.91+ 2.12 and 9.05 + 2.89, GPT 
11.32 + 1.01, and 9.05 + 2.89, total bilirubin 0.72+ 0.181 and 0.69 + 
0.13 and direct bilirubin 0.16 + 0.09 and 0.20+ 0.05 in patients and 
control group respectively, total protein ,albumin and alkaline 
 phosphatase levels have remarkable significant differences between 
study group with a total protein 9.30+ 1.00 and 8.09+0.41 , albumin 
2.50 + 0.37 and 2.94 + 0.92 alkaline phosphatase 265.64 + 4.23 and 
161.05 + 2.05 in patients and control group respectively. 
      As far the level of all of serum albumin, total protein, 
transaminases, alkaline phosphatase and bilirubin in males and 
females in diseased group under the study are concerned, Table (IV) 
and figures (10), (11) and (12) illustrated that there are no differences 
between total protein, albumin, and alkaline phosphatase levels in both 
males and females in CRF patients. In both sexes levels are nearly the 
same. 
     Table (V) and figures (13) and (14) indicated no remarkable 
difference in albumin and total protein levels in patients from different 
age groups. However, alkaline phosphatase, as shown in table (V) and 
figure (15) are remarkably affected by age. The levels of alkaline 
phosphatase is lower in the age group (30-40) compared to the age 
group of (45-74), however, at older ages (69-80) the levels are 
increased. The levels of alkaline phosphatase are affected by age in 
varying degrees, results indicating that patients at younger ages have 
higher levels than the patients of middle age. 
            Table (VI) illustrates the means + standard deviation of albumin, 
total protein and alkaline phosphatase of chronic renal failure patients 
according to family post history of renal and non renal causes; figures 
(16), (17) and (18) show the percentages of the three parameters. 
             Table (VII) illustrates the means + standard deviation of 
albumin, total protein and alkaline phosphatase of chronic renal failure 
patients according to family of renal and non renal causes; figures 
(19), (20) and (21) show the percentages. 
    Table (VIII) represents the source of variation when using ANOVA test 
for the two study groups. 
  
  
  
  
  
  
  
  
Table (I):   
 Average means of serum in patients with minimum  
 and maximum levels.   
        
S.Na+ S.K+S.CreatinineS.Urea Variable 
45 
 
103.74
 
1.22 
 
 
105.00
 
169.00
45 
 
5.09 
 
1.28 
 
 
2.40 
 
8.50
45 
 
9.50 
 
2.65 
 
 
3.50 
 
14.00 
45 
 
146.69 
 
3.91 
 
 
63.00 
 
254.00 
 
N 
 
Mean 
 
Std. 
Deviation 
 
Minimum 
 
Maximum 
  
 S= serum                      
 Std= standard  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
  
  
  
  
  
  
  
  
Table (II):   
Average means of serum in patients with minimum and maximum 
levels.     
 
Direct 
Bilrubin
 
Total 
bilirubin 
ALP GPT GOT ALbTotal 
protien 
Variable 
45 
 
0.16 
 
0.09 
 
 
0.10 
 
60.50 
45 
 
1.05 
 
0.18 
 
 
0.40 
 
1.00 
45 
 
265.64 
 
4.23 
 
 
87.00 
 
992.00 
45 
 
13.20 
 
1.01 
 
 
3.00 
 
54.00
45 
 
21.62 
 
2.12 
 
 
4.00 
 
127.00
45 
 
2.50 
 
0.38 
 
 
2.00 
 
3.60
45 
 
9.34 
 
1.00 
 
 
5.80 
 
11.30 
N 
 
Mean 
 
Std. 
Deviation 
 
Minimum 
 
Maximum 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
  
  
  
  
I):    II  Table (  
Shows comparison between the means of serum total protein (g/dl), 
serum albumin (g/dl), transaminasee (GOT, GPT) U/L, alkaline 
phosphatase U/L and bilirubin (mg/dl) in patients with chronic renal 
 standard The table gives the mean . failure and the control group
deviation.   
P= Probability. 
N=number of cases.   
t test was used for comparison.  
  
 
Variables Grouping N Mean  Std.D P 
 
Serum total 
protein 
 
Serum 
albumin 
 
Serum GOT 
 
 
Serum GPT 
 
 
Serum ALP 
 
 
Serum total  
bilirubin 
 
 
Serum direct 
bilirubin 
 
Patient 
Control 
 
Patient 
Control 
 
Patient 
Control 
 
Patient 
Control 
 
Patient 
Control 
 
Patient 
Control 
 
 
Patient 
Control 
 
45 
20 
 
45 
20 
 
45 
20 
 
45 
20 
 
45 
20 
 
45 
20 
 
 
45 
20 
 
9.34 1.00 
8.09  0.417 
 
2.50  0.38 
2.95  .93 
 
21.63  2.12 
21.73  2.41 
 
11.20 1.01 
9.05 2.8946 
 
265.64 4.23 
161.05 2.05 
 
0.72  0.18 
0.69  0.13 
 
 
0.16  0.09 
0.20  0.05 
 
< 0.05 
 
 
< 0.05 
 
 
> 0.05 
 
 
> 0.05 
 
 
< 0.05 
 
 
> 0.05 
 
 
 
> 0.05 
   
  
  
  
V):                I Table ( 
 Shows comparison between serum total protein (g/dl), serum albumin 
(g/dl) and alkaline phosphatase (U/L) in males and females patients with 
.  standard deviationThe table gives means . chronic renal failure
Probability (P) and N=number of cases.  
Variables sex N Mean  Std.D P 
Total 
protein 
 
Albumin 
 
 
Alkaline 
phosphatase 
Male 
Female 
 
Male 
Female 
 
Male 
Female 
34 
11 
 
34 
11 
 
34 
11 
9.26  1.10 
9.57  0.59 
 
2.49  0.28 
2.64  0.43 
 
   254.44   2.11 
285.36   1.91 
>0.05 
 
 
>0.05 
 
 
>0.05 
  
t test was used for the comparison.   
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
  
):       V Table (   
Shows comparison between serum total protein (g/dl), serum albumin 
(g/dl) and serum alkaline phosphatase (U/L), in deferent grouped   
number of cases=N.  standard deviationThe table gives mean. ages 
 S = serum.  
Grouped 
age N 
S.Total 
Protein S.Albumin 
S.Alkaline 
phosphatase 
15-29 
 
30-44 
 
45-59 
 
60-74 
 
75-89 
9 
 
11 
 
17 
 
7 
 
1 
9.32 0.86 
 
9.09 1.23 
 
9.28 0.96 
 
9.71 0.87 
 
10.60 0.00
2.46 3.05 
 
2.65 1.12 
 
2.54 2.05 
 
2.44 1.70 
 
2.00 0.00 
322.44  0.03 
 
189.18  0.03 
 
293.18  0.03 
 
212.71  0.03 
 
334 0.00 
  
t test was used for the comparison.           
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
Table (VI):    
 Shows comparison between serum total protein (g/dl), serum albumin 
(g/dl) and serum alkaline phosphatase (U/L), in family history of 
 standard The table gives mean . patients with chronic renal failure
deviation.      
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Variable Family history N 
Mean  
Std.D 
 
Albumin 
 
 
ALP 
 
 
protein 
Renal 
Non renal 
 
Renal 
Non renal 
 
Renal 
Non renal 
 
23 
22 
 
23 
22 
 
23 
22 
 
2.60  0.29 
2.44  0.35 
 
320.78 2.55 
200.55 1.10 
 
9.48 1.01 
9.19 0.98 
 Table (VII):        
                        
 Shows comparison between serum total protein (g/dl), serum albumin 
(g/dl) and serum alkaline phosphatase (U/L), in post  history of 
 standard The table gives mean . patients with chronic renal failure
deviation.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     t test was used for the comparison.       
 
 
 
 
 
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
Variable Post history N Mean  Std.D 
Albumin 
 
 
ALP 
 
 
 
Total 
protein 
Renal 
Non renal 
 
Renal 
Non renal 
 
 
Renal 
Non renal 
9 
36 
 
9 
36 
 
 
9 
36 
2.53 0.25 
2.52 1.99 
 
221.67 1.99 
272.08 2.08 
 
 
9.20 1.47 
9.38 0.87 
  
 
 
     Table ( VIII):                                  
     Source of variation by using ANOVA test under the two studies groups 
 
 
F 
 
Sig. 
 
Mean of 
Square 
 
Df 
 
Sum of 
Squares 
 
Source of 
variation 
 
 
Variable 
24.09 
 
 
 
 
 
 
 
8.97 
 
 
 
 
 
 
 
0.00 
 
 
 
 
 
 
 
3.47 
 
 
 
 
 
 
 
 
 
0.00 
 
 
 
 
 
 
 
0.00 
 
 
 
 
 
 
 
0.98 
 
 
 
 
 
 
 
0.07 
 
 
 
 
 
 
 
 
 
20.80 
 
 
0.86 
 
 
 
 
2.79 
 
 
.31 
 
 
 
 
.31 
 
 
491.61 
 
 
 
 
259.26 
 
 
74.64 
 
 
 
 
 
 
1 
 
 
63 
 
 
64 
 
1 
 
 
63 
 
 
64 
 
1 
 
 
63 
 
 
64 
 
1 
 
 
63 
 
 
64 
 
 
 
20.80 
 
 
54.41 
 
 
75.21 
 
2.79 
 
 
19.61 
 
 
22.40 
 
0.31 
 
 
309.71 
 
 
309.71 
 
259.26 
 
 
470.25 
 
 
496.17 
 
 
 
Between 
Groups 
 
Within 
Groups 
 
Total 
 
Between 
Groups 
 
Within 
Groups 
 
Total 
 
Between 
Groups 
 
Within 
Groups 
 
Total 
 
Between 
Groups 
 
Within 
Groups 
 
Total 
 
 
 
Total 
Protein 
 
 
 
 
 
 
Alb 
 
 
 
 
 
 
 
GOT 
 
 
 
 
 
 
 
GPT 
 
 
 
 
 
 
 
 
 
  
5.25 
 
 
 
 
 
 
 
 
0.70 
 
 
 
 
 
 
 
0.50 
 
0.03 
 
 
 
 
 
 
 
 
0.41 
 
 
 
 
 
 
 
0.48 
 
155.49 
 
 
 
29643.06 
 
 
 
 
1.94 
 
 
2.80 
 
 
 
 
28.05 
 
 
56.36 
 
 
1 
 
 
 
63 
 
 
64 
 
1 
 
 
63 
 
 
64 
 
1 
 
 
63 
 
 
64 
 
155.49 
 
 
 
186.75 
 
 
202.30 
 
1.95 
 
 
1.76 
 
 
1.78 
 
28.05 
 
 
355.04 
 
 
357.84 
 
Between 
Groups 
 
 
Within 
Groups 
 
Total 
 
Between 
Groups 
 
Within 
Groups 
 
Total 
 
Between 
Groups 
 
Within 
Groups 
 
Total 
 
ALP 
 
 
 
 
 
 
 
 
Total 
Bilirubin 
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    Figure (3): Comparison between serum total protein means (gm/dl) in        
patients with chronic renal failure (CRF) and control subject.                  
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 Figure.(4): Comparison between serum albumin means (gm/dl) in patients 
with chronic renal failure (CRF).                                                             
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means (U/L) in patients with chronic renal failure (CRF) and control 
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Comparison between serum alkaline phosphatase means ): 7(Figure      
    (U/L)in patients with chronic renal failure (CRF) and control subject. 
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Comparison between serum total bilirubin means ): 8(Figure             
           (mg/dl) in patients with chronic renal failure (CRF) and control 
           subject.  
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Comparison between serum direct bilirubin   means ): 9(Figure 
(mg/dl) in patients with chronic renal failure (CRF)    and control 
subject.  
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                                               4- Discussion 
      In the last years the numbers of patients suffering renal failure 
disease are increasing month after month. Renal dialysis although 
not a cure is used as a mean to sustain life to kidney failure patients. 
    Although studies in animal models have found a favorable 
effect of chronic renal failure on the hepatic functions reduction, the 
result of trials in human are less clear. This study is the first to our 
knowledge to assess prospectively the association between chronic 
renal failure and subsequent decline in the hepatic functions in the 
Sudanese population. In our study chronic renal failure patients 
before heamodialysis have showed the same level of bilirubin and 
transaminases activity as in control group, this indicates that chronic 
renal failure disease which was treated with regular dialysis has no 
effect on these parameters, that no increase or decrease was 
observed.  
  On the other hand, albumin, total protein levels and alkaline 
phosphatase activity   showed remarkable significant differences. 
   This result persisted after adjustment for demographic and 
clinical information, including sex, age, post history and family 
history.  
  Although the liver plays an important role in protein 
metabolism, changes in serum proteins are not specific for the liver 
damage. However detection of change to the various function of 
plasma protein may be of some value. 
 The combination of an absolute low value for serum albumin, 
total protein levels or either of these alone is typical of liver damage. 
Only marked changes of major constituents, such as albumin and 
immunoglobulins, are likely to alter total protein concentrations 
significantly. The finding showed that, albumin concentrations were 
 found to be low in patients with chronic renal failure disease. And 
decrease of about (71.4) of albumin level under the value of the 
control subjects was seen in chronic renal failure patients this may 
indicate that people suffering chronic renal failure have abnormal 
lowering albumin concentrations. 
   In our study total protein concentrations was much higher in 
patients with chronic renal failure disease. These indicate that they 
are increased in immunoglobulin, because albumin is low. 
   The study has show that the age and sex have no effect in level 
of albumin and total protein in patients with chronic renal failure. 
   Alkaline phosphatase is one of enzymes that have been used to 
measure obstructive process in hepatobilirary system. It has 
isoenzymes that are widely distributed throughout the body. By 
measuring the total alkaline phosphatase activity it is impossible to  
a certain the origin of ALP activity. Increase in the alkaline 
phosphatase activity in liver disease is usually in response to 
cholestasis, which may be extra hepatic or intra hepatic. The 
magnitude of increases of alkaline phosphatase due to increases in 
osteoblastic activity or other pathological non hepatic disorders is 
usually more than three times the normal serum level. Values 
indicating cholostasis are usually well above the level associated 
with non hepatic disorders. 
  Our study has reported that the alkaline phosphatase showed 
remarkable significant increase in all patients, it represents less than 
three times the normal serum level. So these results indicate that 
cholestasis was excluded. 
  The study showed that the sex has no effect on the alkaline 
phosphatase level in the chronic renal failure patients but the age 
showed variable differences. On the other hand, urea, creatinine and 
 electrolytes are frequently estimated to show the glomerular 
filtration rate.   
   The study showed that they have no effect of post and family 
history on the total protein and albumin levels and alkaline 
phosphatase activity in patients with chronic renal failure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5-CONCLUSIONS AND RECOMMENDATIONS 
      Conclusions: 
       The liver is the central organ in the body that has important 
metabolic and synthetic functions, beside the major role in the 
detoxification of some substances.  
       There is a abundant evidences that liver functions are reduced in the 
chronic renal failure experimental animals but in human is less clear. 
         In this study we concluded that the bilirubin level and transaminases 
activities results were normal and not affected by chronic renal failure 
disease. Our result extend the alkaline phosphatase activity findings 
were significantly increased but the level of increase was lesser three 
times than normal level of alkaline phosphatase, this result raise the 
possibility that cholestasis was excluded. 
      In addition to that the albumin level was decreased this indicate that 
the level of albumin synthesis was reduced; at the same time results 
from the present study provide that total protein was increased and this 
would be due to the increase in immunoglobulins.  
         Hence the association between the decrease of albumin and increase 
of total protein indicate that there was slight damage in the liver. 
  Recommendations: 
1- More studies investigating the effect of chronic renal failure on liver   
functions and the effect of dialysis are needed. 
2- Electrophoreses to ALP is important that to know the ALP 
isoenzymes to determination the origin which come from.   
3- Increase the centers of dialysis; because the dialysis is a means is 
sustain life to the kidney failure patients.  
4- More work on Sudanese chronic renal failure patients is needed 
to perform more information about the areas where there is increased 
incidence of the disease.  
 5- Conduction of health education programs about the risk factors, 
mode of transmission and protective measure that can be used to 
prevent the spread of the disease.  
6- More information about the disease and the importance of 
compliance should be provided to chronic renal failure patients at the 
time of diagnosis and initiation of therapy.  
7- Organization of community members to participate in the control 
of chronic renal failure disease at community level.  
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                                             APPENDIX  
UNIVERSITY OF KHARTOUM 
Faculty of Veterinary Medicine 
Department of Biochemistry 
                                             Questionnaire  
The effect of chronic renal failure on hepatic functions 
in Sudanese patients 
I- Personal information:  
                     1. Name ………………………………………… 
                    2. Age ……………………………………………… 
3. Sex ………………………………………………… 
             4. Duration of the diseases ……………….………….. 
            5. Residence ……………………………………..…… 
           6. Occupation …………………………………………. 
II- Family history of disease:  
1. Hypertension…………………………………………. 
2. Diabetes mellitus ……………………………………… 
3. Kidney diseases………………………….….………… 
 4. Liver diseases ………………………….….………… 
III- Past history:  
1. Hypertension ………………………………………… 
2. Diabetes mellitus …………………………………… 
3. Malaria ……………………………………………… 
4. Kidney diseases ………………………….….……… 
IV- Investigation:  
1. Serum urea (mg/dl) ………………...……………… 
2. Serum creatinine (mg/dl) …………..……………….. 
             3. Serum electrolyte (mg/dl) …………..………………. 
            4. Serum albumin (g/dl) …………..………………...………… 
5. Serum bilirubin (mg/dl) …………..………………...……… 
6. Serum total protein (g/dl) …………..………………………. 
 7. Serum aspartate amino transferase (U/L) ………….............. 
8. Serum alanine amino transferase (U/L) ……………………. 
         9. Serum alkaline phosphatase (U/L) ………………………….. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 Instruments 
     Vita lab selector: 
    System presentation: 
        The vita lab analyzer is a universal system with a price 
performance relation optimized for small and medium throughput the 
main unit of the system is the analyzer where all liquid handling and 
measurements take place.  A separate computer controls the analyzer 
unit, collects raw data and provides the user interface.  A cooling unit 
permits the system to operate in such a way that it ensures the precision 
of all on board parameters. 
  Analyzer unit: 
The freely programmable analyzer can be used for in vitro diagnosis 
of serum, plasma, CSF and urine, with a maximum through put of 180 
photometric tests per hour in the mono mode or 133 tests per hour in the 
Dual mode. Up to 26 parameters can be determined selectively for one 
patient maple. Thirty two parameters can be loaded on to the respective 
positions of the reagent rotor. 
A total of 60 tests and 15 controls can be programmed per 
programmable reagent disc.  Up to 3 controls can be assigned to each test. 
The required reagent is pipetted by the reagent arm.  Volumes 
between 110Ml and 399Ml are possible for reagent I. Reagent 2 may be 
pipetted with volumes between 10 and 180 Ml (Scriptor. Vita lab 
selector). 
       Including the sample material, volumes between 220Ml and 400Ml 
are allowed.  The reagent arm is equipped with a heating element to warm 
up the cooled reagent prior to use.  The reagent needle is rinsed inside 
and outside after each pippetting process.  Subsequently to pippetting of 
the sample to the prepared reagent, liquids are mixed with the sample 
 needle.  The sample needle is also rinsed inside and outside after each 
pippetting process.  After pippetting of reagent 2, a new mixing process is 
performed, using the reagent needle.  The needle is then rinsed. 
Fifty one patient samples can be positioned in one loading operation 
as soon as all test for a sample are completed, the sample can be removed 
from the sample rotor and replaced by a new sample. The system 
automatically provides a printout of result and evaluations. 
During testing unused positions on the reagent rotor must be covered 
with the supplied caps to ensure optimum cooling and avoid water of 
energy.  The caps also prevent evaporation of the reagents. 
Incubation and measurement are carried out on the reaction or 
cuvettes (path length 7mm, minimum volume 220 Ml) are available, 
incubation is performing at 37°C.  Maximum incubation time is 11.5 
minutes. 
Computer control: 
An external computer provides the user interface to the analyzer 
unit.  The operation software is windows based in order to reduce the 
work expenditure to a minimum.  Test and sample data can be entered via 
the keyboard or a barcode reader connected to the computer (Scriptor. 
Vita lab selector). 
All test results are saved on the external computer and can be printed 
on a printer to his computer. 
Entering sample data and test requests: 
The request samples mean contains all functions required for test 
requests and entry or assignment of patient samples, with a minimum of 
complexity and time you can manually enter sample and patient specific 
data and request the designated tests.  Recorded samples can later be 
edited or deleted.  If needed, the system prints a work list. 
 Define the type of sample in this field.  After pressing enter or 
clicking on the arrow, a drop- down list opens with the choices available. 
Select the type of sample needed: 
normal patient sample, state  emergency sample, pediatrics sample 
of children and teenagers are labeled pediatric, control requests labeled 
with control are recognized by the system as controls, calibrator a request 
labeled labled  calibrator is used to calibrate tests and blank. One position 
on the inner ring of the rotor  research for the reagent blank measurement. 
           In accordance with the programming made in the TEST 
PROGRAMMING menu, the screens display a variable number of tests 
(Scriptor. Vita lab selector).The incoming results of each sample and test 
can be checked and if necessary validated in the EVALUATE SAMPLE 
menu. In the graphic mode the results of a dichromatic end point test, run 
in the DUAL MODE, is displayed. Six points are displayed by the 
system. 
Quality control: 
The quality control menu provides an over view of all measured 
control data. You can select one of the up to three after selection of 
control and corresponding test, you can check the test in the graphic 
mode, e.g. for stability, no graphic representation is displayed for cut off 
tests, test results can be switched directly to PROGRAM CONTROL to 
change assignment of control and to quality control which can even be 
called up during a measuremen 
 
 
 
Calibration:  Elical  
Principle:  
         Elical, a calibrator for automated system, is used for the calibration 
of clinical chemistry analysts. 
Product description: Elical is a lyophilized calibration serum.  
Resents (1) Freeze dried based on human serum. 
Resents (2) Solvent  
Preparation: 
      Carefully open the reagent 1 a voiding the loss of freeze dried 
powdered and pipette exactly 3 ml of solvent (Reagent 2) (Scriptor. Vita 
lab selector). 
      Carefully close the bottle and dissolve the contents completely by 
occasional gentle swirling with 30 minutes a voiding the formation of 
foam. 
Stability of reagent: 
      Prior to reconstitution, when stored at 2.8ºC and protected from light, 
the reagents 1 and 2 are stable until the expiry date stated on the label. 
      After reconstituting stability of components in reconstituted 
calibrator: 4 hours at 25ºC, 2 days at 4ºC and 1 month at -20ºC (only 
freeze once) 
Values: 
The calibration values were determined under strictly standardized 
conditions.  The concentrations of the components are lot- specific. 
Calibration curve: 
Can be done  if three or more standards (maximum 9) are used for 
calibration procedure. By means of this calibration curve the instrument 
will calculate a concentration from absorbance results.  The values of the 
standards must be programmed in the program calibrator screen. 
 
Calculated results: 
 The results calculated test are not performed on the analyzer but are 
derived from applying a calculated test formula to the results of the tests 
that are actually performed on the analyzer.  Up to 10 formulas can be 
defined calculated results are not used for quality control (Scriptor. Vita 
lab selector). 
Flame photometer: 
 One of the most important instroments to estimate electrolyte. It has 
many types and the most important is flame emission photometry (Flame 
photometry). It is used to estimate electrolyte in solution.  
General principle: 
After preparation of solution from serum, the solution is sprayed as 
fine droplets into the flame.  The metal emits radiation or light, the color 
of flame is changed. By characterizing of metal emission light, the light 
wavelength corresponding to element being analyzed is selected by filter 
or spectrophotometer.  The light is allowed to fall in to photo cell convert 
light current and detector (to measure current) and this light is 
proportional to concentration of element being analyzed (Kaplan, etal, 
199). 
Reference values: 
 Reference value of: Total bilirubin < 1.0 mg/dl.  
Reference value of:   direct bilirubin < 0.3 mg/dl. 
Factor total bilirubin 21.6 mg/dl.  
Factor direct bilirubin 16.8 mg/dl. 
Reference value of albumin: 3.8 – 5.4 g/dl. 
Reference value of total protein:  6.2 – 8.0 g/dl. 
Reference value of ALT:  at 37ºC up to 49 U/L. 
Reference value of AST:  at 37ºC up to 46 U/L. 
Reference values of ALP:  at 37ºC Children 180-370 U/L, Adults 100-
290 U/L. 
 Reference values of urea 15-50 mg/dl 0.15 - 050 g/L, 2.50 -8.33 mmol/L. 
Reference values of creatinine: 6 -13 mg/dl 53- 115 mmol/L. 
Normal serum Na+ = 136-149 mmol/L. 
Normal serum K+     = (3.8 - 5.0) mmol/L. 
Low K+ STD = 5.0 mmol/L. 
High K+ STD = 7.0 mmol/L. 
Low Na+ STD = 140 mmol/L.   
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    Figure (3): Comparison between serum total protein means (gm/dl) in        
patients with chronic renal failure (CRF) and control subject.                  
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 Figure.(4): Comparison between serum albumin means (gm/dl) in patients 
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Comparison between serum alkaline phosphatase means ): 7(Figure      
    (U/L)in patients with chronic renal failure (CRF) and control subject. 
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Comparison between serum total bilirubin means ): 8(Figure             
           (mg/dl) in patients with chronic renal failure (CRF) and control 
           subject.  
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                                              4- Discussion 
      In the last years the numbers of patients suffering renal failure 
disease are increasing month after month. Renal dialysis although 
not a cure is used as a mean to sustain life to kidney failure patients. 
    Although studies in animal models have found a favorable 
effect of chronic renal failure on the hepatic functions reduction, the 
result of trials in human are less clear. This study is the first to our 
knowledge to assess prospectively the association between chronic 
renal failure and subsequent decline in the hepatic functions in the 
Sudanese population. In our study chronic renal failure patients 
before heamodialysis have showed the same level of bilirubin and 
transaminases activity as in control group, this indicates that chronic 
renal failure disease which was treated with regular dialysis has no 
effect on these parameters, that no increase or decrease was 
observed.  
  On the other hand, albumin, total protein levels and alkaline 
phosphatase activity   showed remarkable significant differences. 
   This result persisted after adjustment for demographic and 
clinical information, including sex, age, post history and family 
history.  
  Although the liver plays an important role in protein 
metabolism, changes in serum proteins are not specific for the liver 
damage. However detection of change to the various function of 
plasma protein may be of some value. 
 The combination of an absolute low value for serum albumin, 
total protein levels or either of these alone is typical of liver damage. 
Only marked changes of major constituents, such as albumin and 
 immunoglobulins, are likely to alter total protein concentrations 
significantly. The finding showed that, albumin concentrations were 
found to be low in patients with chronic renal failure disease. And 
decrease of about (71.4) of albumin level under the value of the 
control subjects was seen in chronic renal failure patients this may 
indicate that people suffering chronic renal failure have abnormal 
lowering albumin concentrations. 
   In our study total protein concentrations was much higher in 
patients with chronic renal failure disease. These indicate that they 
are increased in immunoglobulin, because albumin is low. 
   The study has show that the age and sex have no effect in level 
of albumin and total protein in patients with chronic renal failure. 
   Alkaline phosphatase is one of enzymes that have been used to 
measure obstructive process in hepatobilirary system. It has 
isoenzymes that are widely distributed throughout the body. By 
measuring the total alkaline phosphatase activity it is impossible to  
a certain the origin of ALP activity. Increase in the alkaline 
phosphatase activity in liver disease is usually in response to 
cholestasis, which may be extra hepatic or intra hepatic. The 
magnitude of increases of alkaline phosphatase due to increases in 
osteoblastic activity or other pathological non hepatic disorders is 
usually more than three times the normal serum level. Values 
indicating cholostasis are usually well above the level associated 
with non hepatic disorders. 
  Our study has reported that the alkaline phosphatase showed 
remarkable significant increase in all patients, it represents less than 
three times the normal serum level. So these results indicate that 
cholestasis was excluded. 
   The study showed that the sex has no effect on the alkaline 
phosphatase level in the chronic renal failure patients but the age 
showed variable differences. On the other hand, urea, creatinine and 
electrolytes are frequently estimated to show the glomerular 
filtration rate.   
   The study showed that they have no effect of post and family 
history on the total protein and albumin levels and alkaline 
phosphatase activity in patients with chronic renal failure.  
 
 
 
 
5-CONCLUSIONS AND RECOMMENDATIONS 
      Conclusions: 
       The liver is the central organ in the body that has important 
metabolic and synthetic functions, beside the major role in the 
detoxification of some substances.  
       There is a abundant evidences that liver functions are reduced in the 
chronic renal failure experimental animals but in human is less clear. 
         In this study we concluded that the bilirubin level and transaminases 
activities results were normal and not affected by chronic renal failure 
disease. Our result extend the alkaline phosphatase activity findings 
were significantly increased but the level of increase was lesser three 
times than normal level of alkaline phosphatase, this result raise the 
possibility that cholestasis was excluded. 
      In addition to that the albumin level was decreased this indicate that 
the level of albumin synthesis was reduced; at the same time results 
from the present study provide that total protein was increased and this 
would be due to the increase in immunoglobulins.  
          Hence the association between the decrease of albumin and increase 
of total protein indicate that there was slight damage in the liver. 
  Recommendations: 
8- More studies investigating the effect of chronic renal failure on liver   
functions and the effect of dialysis are needed. 
9- Electrophoreses to ALP is important that to know the ALP 
isoenzymes to determination the origin which come from.   
10- Increase the centers of dialysis; because the dialysis is a 
means is sustain life to the kidney failure patients.  
11- More work on Sudanese chronic renal failure patients is 
needed to perform more information about the areas where there is 
increased incidence of the disease.  
12- Conduction of health education programs about the risk 
factors, mode of transmission and protective measure that can be 
used to prevent the spread of the disease.  
13- More information about the disease and the importance of 
compliance should be provided to chronic renal failure patients at the 
time of diagnosis and initiation of therapy.  
14- Organization of community members to participate in the 
control of chronic renal failure disease at community level.  
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                APPENDIX  
UNIVERSITY OF KHARTOUM 
Faculty of Veterinary Medicine 
Department of Biochemistry 
                                             Questionnaire  
The effect of chronic renal failure on hepatic functions 
in Sudanese patients 
I- Personal information:  
                     1. Name ………………………………………… 
                    2. Age ……………………………………………… 
3. Sex ………………………………………………… 
             4. Duration of the diseases ……………….………….. 
            5. Residence ……………………………………..…… 
           6. Occupation …………………………………………. 
II- Family history of disease:  
1. Hypertension…………………………………………. 
2. Diabetes mellitus ……………………………………… 
3. Kidney diseases………………………….….………… 
 4. Liver diseases ………………………….….………… 
III- Past history:  
1. Hypertension ………………………………………… 
2. Diabetes mellitus …………………………………… 
3. Malaria ……………………………………………… 
4. Kidney diseases ………………………….….……… 
IV- Investigation:  
1. Serum urea (mg/dl) ………………...……………… 
2. Serum creatinine (mg/dl) …………..……………….. 
             3. Serum electrolyte (mg/dl) …………..………………. 
            4. Serum albumin (g/dl) …………..………………...………… 
5. Serum bilirubin (mg/dl) …………..………………...……… 
6. Serum total protein (g/dl) …………..………………………. 
 7. Serum aspartate amino transferase (U/L) ………….............. 
8. Serum alanine amino transferase (U/L) ……………………. 
         9. Serum alkaline phosphatase (U/L) ………………………….. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 Instruments 
     Vita lab selector: 
    System presentation: 
        The vita lab analyzer is a universal system with a price 
performance relation optimized for small and medium throughput the 
main unit of the system is the analyzer where all liquid handling and 
measurements take place.  A separate computer controls the analyzer 
unit, collects raw data and provides the user interface.  A cooling unit 
permits the system to operate in such a way that it ensures the precision 
of all on board parameters. 
  Analyzer unit: 
The freely programmable analyzer can be used for in vitro diagnosis 
of serum, plasma, CSF and urine, with a maximum through put of 180 
photometric tests per hour in the mono mode or 133 tests per hour in the 
Dual mode. Up to 26 parameters can be determined selectively for one 
patient maple. Thirty two parameters can be loaded on to the respective 
positions of the reagent rotor. 
A total of 60 tests and 15 controls can be programmed per 
programmable reagent disc.  Up to 3 controls can be assigned to each test. 
The required reagent is pipetted by the reagent arm.  Volumes 
between 110Ml and 399Ml are possible for reagent I. Reagent 2 may be 
pipetted with volumes between 10 and 180 Ml (Scriptor. Vita lab 
selector). 
       Including the sample material, volumes between 220Ml and 400Ml 
are allowed.  The reagent arm is equipped with a heating element to warm 
up the cooled reagent prior to use.  The reagent needle is rinsed inside 
and outside after each pippetting process.  Subsequently to pippetting of 
the sample to the prepared reagent, liquids are mixed with the sample 
 needle.  The sample needle is also rinsed inside and outside after each 
pippetting process.  After pippetting of reagent 2, a new mixing process is 
performed, using the reagent needle.  The needle is then rinsed. 
Fifty one patient samples can be positioned in one loading operation 
as soon as all test for a sample are completed, the sample can be removed 
from the sample rotor and replaced by a new sample. The system 
automatically provides a printout of result and evaluations. 
During testing unused positions on the reagent rotor must be covered 
with the supplied caps to ensure optimum cooling and avoid water of 
energy.  The caps also prevent evaporation of the reagents. 
Incubation and measurement are carried out on the reaction or 
cuvettes (path length 7mm, minimum volume 220 Ml) are available, 
incubation is performing at 37°C.  Maximum incubation time is 11.5 
minutes. 
Computer control: 
An external computer provides the user interface to the analyzer 
unit.  The operation software is windows based in order to reduce the 
work expenditure to a minimum.  Test and sample data can be entered via 
the keyboard or a barcode reader connected to the computer (Scriptor. 
Vita lab selector). 
All test results are saved on the external computer and can be printed 
on a printer to his computer. 
Entering sample data and test requests: 
The request samples mean contains all functions required for test 
requests and entry or assignment of patient samples, with a minimum of 
complexity and time you can manually enter sample and patient specific 
data and request the designated tests.  Recorded samples can later be 
edited or deleted.  If needed, the system prints a work list. 
 Define the type of sample in this field.  After pressing enter or 
clicking on the arrow, a drop- down list opens with the choices available. 
Select the type of sample needed: 
normal patient sample, state  emergency sample, pediatrics sample 
of children and teenagers are labeled pediatric, control requests labeled 
with control are recognized by the system as controls, calibrator a request 
labeled labled  calibrator is used to calibrate tests and blank. One position 
on the inner ring of the rotor  research for the reagent blank measurement. 
           In accordance with the programming made in the TEST 
PROGRAMMING menu, the screens display a variable number of tests 
(Scriptor. Vita lab selector).The incoming results of each sample and test 
can be checked and if necessary validated in the EVALUATE SAMPLE 
menu. In the graphic mode the results of a dichromatic end point test, run 
in the DUAL MODE, is displayed. Six points are displayed by the 
system. 
Quality control: 
The quality control menu provides an over view of all measured 
control data. You can select one of the up to three after selection of 
control and corresponding test, you can check the test in the graphic 
mode, e.g. for stability, no graphic representation is displayed for cut off 
tests, test results can be switched directly to PROGRAM CONTROL to 
change assignment of control and to quality control which can even be 
called up during a measuremen 
 
 
 
Calibration:  Elical  
Principle:  
         Elical, a calibrator for automated system, is used for the calibration 
of clinical chemistry analysts. 
Product description: Elical is a lyophilized calibration serum.  
Resents (1) Freeze dried based on human serum. 
Resents (2) Solvent  
Preparation: 
      Carefully open the reagent 1 a voiding the loss of freeze dried 
powdered and pipette exactly 3 ml of solvent (Reagent 2) (Scriptor. Vita 
lab selector). 
      Carefully close the bottle and dissolve the contents completely by 
occasional gentle swirling with 30 minutes a voiding the formation of 
foam. 
Stability of reagent: 
      Prior to reconstitution, when stored at 2.8ºC and protected from light, 
the reagents 1 and 2 are stable until the expiry date stated on the label. 
      After reconstituting stability of components in reconstituted 
calibrator: 4 hours at 25ºC, 2 days at 4ºC and 1 month at -20ºC (only 
freeze once) 
Values: 
The calibration values were determined under strictly standardized 
conditions.  The concentrations of the components are lot- specific. 
Calibration curve: 
Can be done  if three or more standards (maximum 9) are used for 
calibration procedure. By means of this calibration curve the instrument 
will calculate a concentration from absorbance results.  The values of the 
standards must be programmed in the program calibrator screen. 
 
Calculated results: 
 The results calculated test are not performed on the analyzer but are 
derived from applying a calculated test formula to the results of the tests 
that are actually performed on the analyzer.  Up to 10 formulas can be 
defined calculated results are not used for quality control (Scriptor. Vita 
lab selector). 
Flame photometer: 
 One of the most important instroments to estimate electrolyte. It has 
many types and the most important is flame emission photometry (Flame 
photometry). It is used to estimate electrolyte in solution.  
General principle: 
After preparation of solution from serum, the solution is sprayed as 
fine droplets into the flame.  The metal emits radiation or light, the color 
of flame is changed. By characterizing of metal emission light, the light 
wavelength corresponding to element being analyzed is selected by filter 
or spectrophotometer.  The light is allowed to fall in to photo cell convert 
light current and detector (to measure current) and this light is 
proportional to concentration of element being analyzed (Kaplan, etal, 
199). 
Reference values: 
 Reference value of: Total bilirubin < 1.0 mg/dl.  
Reference value of:   direct bilirubin < 0.3 mg/dl. 
Factor total bilirubin 21.6 mg/dl.  
Factor direct bilirubin 16.8 mg/dl. 
Reference value of albumin: 3.8 – 5.4 g/dl. 
Reference value of total protein:  6.2 – 8.0 g/dl. 
Reference value of ALT:  at 37ºC up to 49 U/L. 
Reference value of AST:  at 37ºC up to 46 U/L. 
Reference values of ALP:  at 37ºC Children 180-370 U/L, Adults 100-
290 U/L. 
 Reference values of urea 15-50 mg/dl 0.15 - 050 g/L, 2.50 -8.33 mmol/L. 
Reference values of creatinine: 6 -13 mg/dl 53- 115 mmol/L. 
Normal serum Na+ = 136-149 mmol/L. 
Normal serum K+     = (3.8 - 5.0) mmol/L. 
Low K+ STD = 5.0 mmol/L. 
High K+ STD = 7.0 mmol/L. 
Low Na+ STD = 140 mmol/L.   
 
 
  
 
